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ABSTRACT 
 
 
 
Background: Hospital care utilization has been described as a key measurable indicator of care 
quality in patients with terminal respiratory diseases. Knowledge about patterns in service 
utilization for patients with advanced Chronic Obstructive Pulmonary Disease (COPD), 
however, is fairly limited. The goal of this study was to investigate health care utilization 
patterns in the last six months of life among patients who died with COPD compared with those 
who died of lung cancer, and also to examine variations in health care among individuals living 
with COPD between sex, age, comorbidity, and temporal trends. 
 
Methods:  We conducted a retrospective study using administrative health data in the province 
of Saskatchewan to identify indicators associated with greater hospital care utilization between 
1997 and 2006. Those with either COPD or lung cancer as the underlying cause of death 
(UCOD) were included in this study. Characteristics examined in this study included socio-
demographics, comorbidity, location of death, and use of institutional services. Multiple logistic 
regression was the primary method of analysis. 
  
Results: Between 1997 and 2006, 7,114 persons covered by Saskatchewan Health were 
identified as having COPD (N=2,332) or lung cancer as the UCOD (N=4,782). Approximately 
60% were males with an average age of 74.2 years (S.D. =10.1 years).  
Half of the decedents were rural dwellers (47.0%), and were married or common law (51.6%). 
The majority had multiple comorbid conditions (60.3%), died in hospitals (73.5%), and had 
never received services from long-term supportive care institutions (74.3%). Compared with 
those who died from lung cancer, people dying from COPD were less likely to be admitted to 
hospitals (OR=0.71, 95%CI: 0.64-0.80 in the last six months of life; OR=0.81, 95%CI: 0.70- 
0.93 in the last month of life) and had shorter LOS for each admission (OR=0.78, 95%CI: 0.70-
0.87 in the six months of life; OR=0.67, 95%CI: 0.60-0.75 in the last month of life). However, 
  
 
III 
persons with COPD were more likely to be managed in an intensive care settings (5.3% of 
COPD subjects vs. 1.7% of lung cancer subjects in the last six months of life; 4.3% of COPD 
subjects vs. 0.06% of lung cancer subjects in the last month of life) and had higher numbers of 
transfers between long-term care facilities (7.7% of COPD subjects vs. 3.2% of lung cancer 
subjects). Between 1997 and 2006, there was no significant change in the hospital utilization 
among patients who died of COPD or those who died of lung cancer. 
 
Conclusions: Marked differences in terms of hospital service utilization in the last six months of 
life were observed between subjects dying with COPD and lung cancer. Our study results 
support previous work indicating that the nature of care management at the end of life for people 
who died of advanced COPD is different from those who died from lung cancer, which was 
reflected by reduced likelihood of hospital service usage, more ICU admissions, and frequent 
transfers between supportive care facilities. There is no significant change observed regarding 
the patterns of hospitalization over 10-year study period. We would suggest collecting more 
information on services managed in other care settings, such as emergency departments, out-
patient settings, and clinics, etc. This would allow an in-depth examination regarding what types 
of institutional services influenced the usage of in-patient care. In addition, education of all 
health care professionals on the complex needs of patients living with respiratory illnesses is 
required. 
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Chapter 1: INTRODUCTION & RATIONALE 
1.1 Introduction 
Based on estimates from Statistics Canada in 2008, chronic respiratory diseases, including lung 
cancer and Chronic Obstructive Pulmonary Disease (COPD), were the fourth leading causes of 
death among Canadians [1]. COPD is a common respiratory disease, characterized by increasing 
breathlessness, functional impairment, and steadily deteriorating quality of life. Recent literature 
indicated that women diagnosed with COPD tend to fare worse than men, with female patients 
being more likely to be hospitalized from COPD [2]. Unfortunately, for patients with advanced 
COPD, the large amount of variability in COPD progression makes accurate prognostication 
difficult.  
 
As the number of COPD-related deaths is expected to increase in the future, there is an 
increasingly urgent need to understand key issues in this disease’s trajectory at the end of life.  
There remained significant opportunities to improve the quality of care for the COPD population. 
In contrast to COPD, lung cancer received a great deal of attention and a number of indicators 
were developed that may serve as proxies for evaluating quality of care at the end of life 
including the number of hospitalizations and information around hospitalization such as time 
spent in ICU, emergency department visits, or medical ventilator usage.  
 
1.2 Rationale 
Trends in hospital care utilization have been described as an important measurable indicator of 
care quality in patients with terminal respiratory diseases; however, knowledge about trends in 
hospitalization for patients with advanced COPD remains limited. In addition, the impact of sex 
on hospitalization trends among the population with advanced COPD has received little attention 
in the past. Given the lack of focus on this variable in past studies, differences between the sexes 
should be a focal point in these analyses.  To better understand these gaps in knowledge, this 
analysis seeks to evaluate the trends in hospitalization among those who died from COPD or 
lung cancer. In addition, the current study aimed to examine the association between sex, age and 
comorbidity with hospitalization.  
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1.3 Objectives and Research Questions 
The overarching objective of this thesis was to investigate health care utilization patterns (i.e. 
hospitalizations) in the last six months of life among patients aged 50 years or above who died 
with COPD compared with those who died of lung cancer, and also to examine variations in 
health care utilization among individuals based in key personal characteristics. 
 
More specifically, the research questions were:  
1. How do indicators of hospitalization including the number of ICU and inpatient days in the six 
months prior to death compare between patients with a diagnosis of COPD and those with a 
diagnosis of lung cancer?  
2 Is there an association between the following independent variables and hospitalization among 
the target population and do they modify the effect of diagnostic group? 
 (a) age 
 (b) comorbidity 
 (c) sex 
3. Does the pattern of hospitalization change over a 10 year period and are the associations 
between hospitalization and diagnostic group, age, sex, and comorbidity consistent over the 10 
year period? 
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Chapter 2: LITERATURE REVIEW 
2.1 Selection of Articles for Inclusion in the Literature Review 
The purpose of the study was to examine differences in hospitalization patterns and reasons for 
hospitalization among patients with COPD when compared to patients with lung cancer, to 
assess their association with sex, age and comorbidities, and to consider temporal changes in 
these trends. To aid in this purpose, this literature review describes the epidemiology of COPD 
and lung cancer, including morbidity and mortality rates globally and across Canada, as well as 
well-established indicators associated with health care utilization from studies of patients with 
lung cancer. Searches of the literature were conducted using PUBMED database and Google 
scholar. The search included articles from 1997 to 2014. Search terms or keywords included but 
were not limited to “COPD”, “Lung cancer”, “epidemiology”, “palliative care”, “hospitalization”, 
“time trends”, “mortality”, and “end-of-life”. The search was limited to adults aged 50 years and 
above who were diagnosed with COPD or lung cancer. These terms were searched separately 
and in combination. 
 
From this search, 26 articles examined the patterns of hospitalization for the study population. 
Among those, eight articles described the trends in hospitalization among the COPD population 
during their last phase of life while eighteen papers examined the patterns among the lung cancer 
population. Eight articles were selected regarding the indicators associated with hospitalization. 
For the epidemiology (time trends on prevalence) of lung cancer and COPD, there were 135 
papers. Twenty-four articles focused on COPD and 111 focused on lung cancer. With regard to 
trends on mortality among COPD and the lung cancer population, there were fourteen papers. 
Two papers examined the patterns of mortality in COPD populations, and twelve papers focused 
on the frequency and incidence in the lung cancer group. 
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2.2 COPD 
COPD is a chronic lung disease, which is characterized by progressive airflow obstruction. 
COPD consists of chronic bronchitis and emphysema. The most common symptoms of COPD 
include chronic and progressive dyspnea, cough, and sputum production that can vary daily [3].  
 
2.2.1 Recent trends in the prevalence and incidence of COPD 
2.2.1.1 Global  
COPD is recognized as a disease that leads to chronic impairment of health functions and causes 
significant mortality and morbidity among patients. COPD affects approximately 340 million 
people worldwide [4]. According to the Centers for Disease Control and Prevention, the 
prevalence of COPD in the United States remained steady between 1998 and 2009 with rates that 
were higher in women (6.1%) than in men (4.1%) [5]. During the period from 1997 to 2007, 
based on a report from the United Kingdom, the prevalence of physician-diagnosed COPD in 
women (1.8%) also exceeded that in men (1.5%) [6]. A study from the Netherlands suggested 
that there would be a 76% increase in the prevalence of COPD by 2015 compared with that in 
1994[7]. 
 
2.2.1.2 Canada 
COPD is recognized as a highly prevalent respiratory disorder among Canadians. A population-
based cohort study suggested that the prevalence of COPD increased by 23.0% from 1980 to 
1995 [8]. Based on a report from Statistics Canada, 4.8 percent of Canadian women had to cope 
with COPD compared with 3.9 percent of men [5]. According to estimates, in the year 2005, 
425,300 Canadian women 35 years of age or older self-reported a diagnosis of chronic 
obstructive pulmonary disease compared with 329,500 Canadian men [9]. In comparison with 
other provinces, Saskatchewan had a relatively low COPD prevalence. In 2003, Saskatchewan 
prevalence estimates ranged from 4% to 5% of the population aged 45 years and older. These 
figures were far below the prevalence in the Maritime Provinces, which ranged from 8% to 10% 
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of the study population [10]. The observed lower prevalence in Saskatchewan may be due to 
smoking rates that are lower than that in the Maritime Provinces as cigarette smoking is 
considered as the primary risk factor or COPD [11]. The exclusion of high-risk populations such 
as First Nations people contributed to the low prevalence of COPD in the Saskatchewan 
population. Previous studies suggested that there was a steady growth in the prevalence of COPD 
in Saskatchewan, with the biggest rise seen in the Registered Indian population [13]. However, 
they were usually excluded from population health research or were not captured in the 
administrative data.  
 
2.2.2 Mortality 
2.2.2.1 Global 
According to the World Health Organization (WHO), in 2002, COPD was ranked as the fifth 
most common cause of death and remained the only common cause of respiratory mortality that 
was increasing in incidence globally [9]. By the year 2020, experts predicted that COPD would 
become the third leading cause of death across the world [15]. Studies in North America also 
stated that the COPD-specific mortality was found to be increasing over the last decade [16, 17]. 
According to the COPD Disease Surveillance in the U.S., there was a fivefold increase in 
mortality rate due to COPD in women between 1971 and 2000[18]. Statistics estimated that 
Chronic Lower Respiratory Disease (CLRD), which consisted of both COPD and asthma, was 
the third leading cause of death in 2008 in United States [19]. In the UK, the male age 
standardized mortality rates from COPD were found to have progressively decreased over the 
last 30 years; while, in women, the report estimated a small but progressive increase over the last 
20 years [20]. In addition, advanced COPD is also marked by slow deterioration with 
intermittent occasions of potentially fatal acute exacerbation. According to a Spanish study in 
2002, the mortality rate for severe COPD was as high as 50% after admissions for an acute 
exacerbation [21].  
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2.2.2.2 Canada 
In Canada, COPD was the fourth leading cause of death in 2010, with the highest mortality rate 
in the Northwest Territories [22]. Although the 5-year survival rate for patients living with 
COPD ranges from 30% to 40%, it falls to 23% with the severe cases [22]. Furthermore, an 
upward trend was observed in the number of deaths caused by COPD among Canadians between 
the years 1987 to 2014. According to Camp et al., the largest increase was witnessed in the 
population aged 75 years and above [10]. Additionally, there is evidence that women are more 
affected by COPD than men in terms of functional health, which is partly reflected as significant 
growth in terms of mortality. Statistics reported that COPD was the fourth-ranked cause of 
mortality among Canadian males aged 65 years and over between 1984 and 1993. Meanwhile, 
COPD was the seventh-ranked cause of death among women aged 65 years and over during the 
same period [1]. COPD mortality rates in men increased steadily since the early 1960s but since 
the mid-1980s stabilized and started to decline. In women the rates continued to increase 
unabated [6].  
 
2.3 Lung cancer 
Lung cancer is defined as an unregulated growth in the tissues of the lungs. The main types of 
lung cancer are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). 
The majority (85%) of lung cancer diagnoses are NSCLC, while SCLC consists of 15% [23]. 
The characteristic symptoms include cough, weight loss and shortness of breath [23]. 
 
2.3.1 Recent trends in the prevalence and incidence of lung cancer 
2.3.1.1 Global 
Cancer accounted for a substantial proportion of morbidity and mortality worldwide in the 
twenty-first century [1, 2, 9]. Experts predicted that the number of new cases of cancer would be 
more than 15 million by the year 2020, and the number of deaths was projected to be 12 million 
[1]. In addition, lung cancer was recognized as the most commonly diagnosed cancer globally in 
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2008 [2, 9]. According to the report of Global Cancer Statistics, the highest lung cancer 
incidence rates were found in North America (42.2 per 100,000 population per year), followed 
by Europe (33.4 per 100,000 population per year) and Australia (25.6 per 100,000 population per 
year) [24].  
 
2.3.1.2 Canada 
In Canada, lung cancer was one of the most three common cancers among both males and 
females. Similar to the patterns observed globally, the incidence of lung cancer in Canada was 
rising. In 2010, there were more than 24,000 Canadians who were diagnosed with lung cancer 
[25]. In 2007, among females, the number of new cases for lung cancer has tripled since 1976 
[25]. In 2005, the incidence rates of lung cancer among women were reported to be more than 
half of those among men [25]. 
 
2.3.2 Mortality 
2.3.2.1 Global 
Despite advances in the early detection and treatment of cancer, according to the WHO, it was 
still reported as the leading cause of death worldwide, accounting for 13% of all deaths in 2008 
[26]. Lung cancer was the leading cause of cancer death in males in 2008 globally. Among 
females, it was the second leading cause of cancer death [24]. In the United States, lung cancer 
caused the most cancer-related deaths from 1998 to 2009 [27]. In 2006, lung cancer made up 
approximately one quarter of all cancer deaths in the United States [28]. In Europe, lung cancer 
accounted for 20% of all cancer deaths [10]. In particular, lung cancer was recognized as the 
most common cancer leading to death in men and the second most common cancer in women in 
the UK [10].  
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2.3.2.2 Canada 
In 2010, lung cancer accounted for nearly one third of all cancer-related deaths in Canada [29]. 
The total number of individuals who died of this disease was more than the number of deaths 
from prostate, breast and colorectal cancers combined [30]. Moreover, lung cancer remained the 
leading cause of cancer death in Canadian women in 2005, accounting for an estimated 8,300 
deaths [30]. According to Canadian Cancer statistics, in 2012, lung cancer was the most common 
cause of cancer related deaths for both males and females in Saskatchewan [31]. 
 
2.3 Summary of findings for frequency and mortality for COPD and lung cancer 
Lung cancer has been identified as the leading cause of cancer-related mortality for both sexes 
globally and across Canada [13, 29]. COPD also had an increasing burden worldwide, reported 
to be the fifth most common cause of death in 2007 [9], and projected to be the third by 2020 
[15]. As suggested by earlier research, the mortality rate from COPD may be underestimated 
resulting from difficulty in distinguishing between various causes of deaths in clinical settings 
[32].  Where obstructive lung disease was mentioned but not the underlying cause of death, the 
other most common causes were heart disease and lung cancer. COPD was more likely to be 
reported as a contributing rather than underlying cause of death or morbidity, or might not be 
reported at all [94]. 
 
2.4 End-of-life Care 
End-of-life care, a more humane and appropriate alternative to aggressive health-care 
intervention, is defined as “the active, total care of patients whose disease is not responsive to 
curative treatment” [34]. Thus, it aims for providing less aggressive, less expensive, more 
patient-centered holistic care for patients living with end-stage illnesses in order to achieve the 
best possible quality of life. According to the Canadian Hospice Palliative Care Association 
(CHPCA), the dramatically increasing demand for palliative care services in the next 40 years 
should be considered as a top priority [35]. The hospital is considered an important setting to 
deliver end-of-life care services since virtually all patients entering the final six months of life 
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spend at least some time in a hospital, usually on multiple occasions [36]. Moreover, a growing 
body of literature suggested the consumption of palliative care services was associated with a 
significant improvement in quality of life and a notable reduction in the use of aggressive care 
services near the end of life. Unfortunately, based on a Canadian study in 2007, only one third of 
the decedents across Canada had ever received palliative care services. Furthermore, it was also 
observed that palliative care services across Canada were unevenly distributed. Rural dwellers, 
or those living with disabilities, had severely limited access to formal palliative care services 
[35]. 
 
2.4.1 The End-of-life Trajectory for People with COPD 
According to the National Council for Palliative Care (NCPC), less than half of health facilities 
in the U.S. explicitly considered the needs and wishes of dying people [32]. As cited by 
Richardson, overlooking end of life care in major strategies would lead to costly fragmentation 
in care and support that failed to meet patients' needs [37]. Based on the evidence from the 
scientific literature, COPD patients at the end of life suffered neglect from health care 
professionals [38], leaving the growing need for a quality end-of-life care significantly more 
important and relevant. 
 
Patients who died from COPD fared far worse, in terms of end-of-life care, than those who died 
from lung cancer [39]. They received fewer palliative care services, were more likely to receive 
invasive therapy, and were more frequently admitted to ICU, although both groups experienced 
heavy symptom loads near the end of life, including physical and psychological afflictions [39, 
40]. Moreover, patients with end-stage COPD suffered from a poor quality of life in regards to 
higher degrees of social isolation, lower physical functioning, as well as higher levels of 
disability as indicated by an earlier UK report [18]. One possible explanation was the difficulties 
in making an accurate prognosis among patients living with advanced COPD. As indicated by 
previous report, almost half of the deceased subjects were not aware that they might die, even 
though they had had more than two hospitalizations [41]. In addition, such differences in care 
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might also result from variations in patients’ attitudes towards care services they’ve received, 
their preferences regarding end-of-life care, differences in physicians’ preferences and attitudes, 
and some combination of these factors. Furthermore, it is well acknowledged that patient living 
with COPD, particularly those with poor prognosis, suffer from a significantly higher burden of 
depressive or anxious symptoms than those with lung cancer. The presence of depression or 
anxiety may influence the patient’s ability to understand the impact of decisions that they make. 
Moreover, it may have an impact on physician’s decision-making regarding end-of-life 
treatments. 
 
Apart from the unpredictable disease prognosis, it was also difficult for the physicians to start the 
end-of-life discussions. An earlier American study on end-of-life communication found that, 
from July 1999 to June 2002, nearly three quarters of the patients would rather talk about staying 
alive than dying [41]. Previous work by Gore and colleagues also suggested that palliative care 
resources were not in place to meet the needs of individuals dying of COPD [42].  In marked 
contrast, when a diagnosis of lung cancer was made, the focus was not only on maximizing the 
survival possibility but also on quality of life with respect to physical and emotional wellbeing, 
as suggested by Claessens and colleagues [39].  
 
With COPD diagnoses and deaths on the rise, patients with terminal COPD require quality 
palliative care to alleviate their suffering. Previous research that investigated the quality of life 
among COPD patients at the end of life suggested that a severe impact of the disease and the 
considerable needs of quality healthcare services were evident, and end-of-life care for patients 
living with advanced COPD merited more attention from clinicians, researchers, and policy-
makers.  
 
  
 
11 
2.4.2 End-of-life care for lung cancer 
Despite the rapid development of the technological and chemotherapeutic science, treatment 
options for lung cancer are still limited. Based on evidence from scientific literature, the 5-year 
survival rate in Canada was around 17% in this population [43], leaving lung cancer as the 
leading cause of cancer-related deaths nationally; therefore, end-of-life care for this population 
should be stressed as a top priority.  
 
Compared with individuals who died of COPD, patients who died from lung cancer reported a 
relatively satisfactory experience during their last phase of life, including better symptom 
management, higher emotional status, more communication with health care professionals, and 
were more likely to die at home or in a hospice setting [44]. However, previous reports suggested 
an impaired quality of life among patients living with lung cancer. According to Price and 
colleagues in 2009, many patients with lung cancer continued to suffer not only from pain, but 
also from other symptoms related with physical and emotional discomfort in their final days [45].  
 
According to a national survey, 1.2 million Americans with cancer were admitted to hospital in 
2002. In addition, this figure was expected to increase as a result of a growing and aging cancer 
population [46]. These justified the call for the development of effective end-of-life care for 
patients with serious and complex illness, such as lung cancer. According to the Lung Cancer in 
Canada report in 2010, the aim of end-of-life cancer care was to improve the quality of life 
among terminally ill patients by relief of suffering, practical support need, open communication 
and effective management of concerns [29]. 
 
Death from chronic respiratory diseases follows a course of functional decline with acute 
exacerbation. Based on the work by Pot and colleagues in 2009, patients who died from COPD, 
when compared with those who died from lung cancer, unfortunately had relatively 
  
 
12 
unsatisfactory care management, both physical and psychosocial, leaving the COPD population 
an important group to consider in end-of-life care research [47]. 
 
2.5 Potential Indicators 
The use of indicators has been acknowledged as one approach for identifying key areas for 
improvement in end-of-life care. Additionally, administrative databases have been recognized as 
useful and economical tools from which to draw indicators that measure the quality of end-of-life 
cancer care.  
 
Five quality indicators specific to cancer care were identified by Earle et al. based on 
administrative data in the U.S.: 1) hospital as place of death, 2) short interval between last 
chemotherapy dose and death, 3) frequent emergency department visit, 4) high number of 
hospital and intensive care unit (ICU) days near the end of life, 5) low proportion of patients 
enrolled in hospice and hospice enrolment very near death [30]. Building on the work of Earle 
and colleagues, Canadian studies were conducted utilizing administrative databases to determine 
quality indicators among terminal cancer patients [36]. Since COPD’s disease trajectory is less 
predictable than that of cancer, it is more difficult to predict the optimal time to provide 
palliative care for those suffering from COPD. 
 
2.5.1 Hospitalization 
Building on previous studies, hospitalization was identified as a measurable indicator for 
investigating the quality of end-of-life cancer care. Although many of the patients with 
respiratory disorders were not hospitalized for their disease, hospitalization represented a major 
contribution to the socio-economic burden of chronic respiratory diseases. As a person 
approached the end of life, the consumption of acute hospital services increased, especially in the 
last thirty days of life. This was supported by a study from Teno and colleagues [48]. According 
to the literature, significant reductions in hospitalizations were associated with a significant 
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improvement in relieving patients’ financial stress [49, 50]. This was particularly important in 
systems lacking universal health coverage. 
 
In addition, prolonged LOS in hospital was projected to increase the chance for readmission [34]. 
Longer stay in a hospital setting was also associated with a poorer quality of life as a result of a 
high degree of social isolation, poor disease prognosis, and emotional distress [43].    
 
According to Anthonisen et al., in 2002, respiratory diseases accounted for three fourths of all 
hospitalizations in Canada [51]. In 2009, lung cancer was the third most common cause of cancer 
hospitalization among Canadians, placing an enormous economic burden on the health care 
system [45]. In Alberta, the cost associated with lung cancer hospitalization was $8.4 million 
[52].  
 
With regard to hospitalization among the COPD population, the Northwest Territories had the 
highest hospitalization rate in Canada between 1996 and 1999, with 3,082 hospitalizations for 
COPD per 100,000 in the 55 years and older population [10]. In marked contrast, British 
Columbia had the lowest rate (555 hospitalizations per 100,000 population) [22]. The figure for 
patients living with COPD in the U.S. was 726,000 in 2000 [54]. An acute exacerbation was 
recognized as a primary cause of hospital readmission in the COPD population [44]. According 
to Camp et al., one out of ten COPD patients was re-hospitalized within 15 days after an acute 
exacerbation, leaving COPD the third most common cause for readmission in Canada in 2009 
[10]. Individuals with COPD were also reported to have a longer hospital stay when compared 
with individuals with other diseases. However, previous research that evaluated the needs for 
healthcare services suggested deceased COPD patients received inadequate services from 
primary and secondary care in their last year of life [46]. 
 
  
 
14 
2.5.2 Intensive Care Unit (ICU) Admission 
Increased demand for health services from an aging population, coupled with an influx of new 
technologies, is placing increasing pressures on health care systems [53]. According to the 
Statement of the 5th International Consensus Conference in Critical Care, the goal of optimal 
care for patients dying in intensive care settings is to provide relief from distressing symptoms, 
to integrate the spiritual aspect when caring for patients, and to offer support to the patients as 
well as their families [54].  
 
The ICU visit can be considered an indicator of poor quality of life among patients in their last 
phase of life, although the provision of critical care is primarily dependent upon the severity of 
illness. It was suggested that aggressive treatment should be stopped and supportive care services 
should be put in place when a person was close to death [55]. However, intensive care services 
were often allocated to those who entered the final stage of the dying process. Teno and 
colleagues found that, in the last thirty days of life, approximately one in three patients receiving 
hospice care were admitted to ICU in 2009 [48], which was consistent with an earlier study of 
patients with cancer [30]. Au and colleagues suggested that ICU use might be ineffective in 
patients with terminal illness in terms of financial cost, physical and emotional burden for 
patients, family members, and health-care providers [56].  
 
According to Keenan et al., ICU admissions were found to directly translate to increased 
healthcare costs [53]. Additionally, the terminal ICU admission accounted for 80% of all 
terminal hospitalization costs [53]. Other findings suggested that in order to address the fiscal 
burden within the health care system, ample savings could be realized through the improvement 
in efficiency of high-cost services, such as ICU [55]. Frequent ICU attendance also placed strain 
on hospital bed availability, resulting in longer waiting times for other patients [55]. Nowadays, 
this issue became more pronounced in light of human resources in hospital settings, which 
provided another reason why ICU utilization was a subject of public concern [18]. Since ICU 
demanded special resources, for example, a low patient–nurse ratio was required for careful 
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titration of intravenous medication to control dyspnea during ventilator withdrawal; increased 
ICU usage was believed to further contribute to a national shortage of nursing staff. Previous 
research suggested that the use of hospice care services help avoid unnecessary consumption of 
aggressive care services, leaving a decreased financial burden on the health care system. Earle 
and colleagues found that individuals residing in regions with greater access to hospice services 
had a reduced likelihood of being admitted to intensive care settings at the end of life [30]. On 
the other hand, some advanced techniques used in the intensive care settings may have harmful 
side effects or may reduce the quality of life for the patient, but they save lives. When a person is 
very close to death, the question of whether death itself is a harm and whether the harm caused 
by the treatment outweighs the improved quality of life from palliative care program needs to be 
considered. 
 
A growing body of literature found that an increasing proportion of patients with terminal 
respiratory diseases received ICU services near the end of life [56-59]. A prospective study 
designed to identify the potential factors of prolonged length of stay (LOS) in ICU showed that 
patients living with critical respiratory diseases were more than twice as likely to have a 
prolonged stay and to consume large amounts of critical care resources [57]. Another Canadian 
study also demonstrated that subjects with lung cancer consumed a greater amount of care 
services in ICU compared with COPD participants in 2008 [58]. However, a study in the United 
States in 2006 demonstrated that COPD patients had approximately twice the odds of receiving 
ICU service, five times the odds of staying at ICU two weeks or longer compared with patients 
afflicted with lung cancer [56]. A study conducted by Sharma and colleagues in 2008 claimed 
that there were no significant differences in mean or median LOS in ICU among decedents living 
with severe respiratory diseases; however, among those suffering from a respiratory disorder, 
nearly forty percent of ICU users had three or more hospitalizations in the last six months of life 
compared to one quarter of non-ICU users [59].  
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2.5.3 Factors influencing Hospital and ICU usage 
Based on evidence from the scientific literature, hospital and ICU utilization were associated 
with a number of patient characteristics, including age, sex, and comorbid conditions. Female 
patients were more likely to have a prolonged LOS in hospital, but reported less frequent ICU 
admissions [60, 61]. Age was confirmed as an important factor influencing hospital and ICU 
usage [18, 62].  In the last phase of life, the use of hospital services was predicted by younger 
age [63], whereas an aggressive end-of-life service was associated with advanced aging [42]. 
Individuals with more co-existing illness were high utilizers of health care services [53-57, 62-
64]. The overall impacts from both age and comorbidity were found to be much higher than the 
effect of age alone [65]. Other factors also contributed to the increased consumption of 
hospitalization. For both lung cancer and COPD patients, those with high socioeconomic status 
reported higher accessibility to health care services, such as ICU care, than those with lower 
socioeconomic status [66]. More importantly, tobacco consumption was well-known as a strong 
predictor for developing lung diseases [29], having longer LOS in hospitals, and a higher 
likelihood of admitted to ICU settings among this population [67].  
 
2.5.3.1 COPD  
Sex 
The role of sex in hospitalization and ICU use trends remained unclear and is the topic of a great 
deal of research. The trends of hospitalization in 1997, in a Danish study, were reported to 
correspond with mortality trends, decreasing in men and increasing in women [60]. Since more 
elderly females than males lived alone, this might contribute to a higher proportion of females 
being hospitalized [68]. Another possible explanation was suboptimal care management, which 
was shown in a study in cardiovascular disease [61]. Suboptimal management is described as a 
failure to provide appropriate and timely interventions to patients. According to Gan and 
colleagues, women with the same degree of lung disease did not receive as much aggressive care 
services as the male patients, which increased the likelihood of females being hospitalized in the 
later stage [61]. This type of bias could also exist in patients with COPD since it has historically 
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been considered a disease of men. According to the CDC, from 1999 through 2007, COPD 
hospitalization rates declined for both men and women in the United States [5]. In Singapore, the 
hospitalization rate in 1994 for those aged 65 years and above was 93.0 per 10,000 [69]. COPD 
hospitalization rates in Singapore men were similar to rates in Canadian men, but for women, the 
rates in Canada were 2 to 8 times higher [69].  
 
Based on evidence from the scientific literature, female patients living with COPD were more 
likely to report more severe disease symptoms. According to a Spanish study in 2005, female 
subjects had a higher degree of dyspnea than the males even though they suffered fewer 
comorbid illnesses and had better oxygenation [70]. In addition, there was no significant 
difference observed in terms of hospitalization rate between sexes. There were also studies that 
reported no significant differences between sexes in terms of hospitalization and ICU use [71, 
95]. According to a Spanish study from Watson and colleagues in 2004, the variation between 
sexes in terms of the number of hospital admissions was not statistically significant [66].  Based 
on a Canadian study in 2005, Menec and colleagues suggested that ICU use did not differ 
significantly by sex [72]. However, based on the work by Prescott and colleagues, females had 
an increased risk of hospitalization for COPD compared with males [67]. The findings from 
Prescott and colleagues were also in agreement with a Canadian study where hospitalization was 
found to be associated with female sex [51]. In marked contrast, based on an earlier U.S. study in 
2002, Wolff and colleagues found the opposite, suggesting that female patients have a decreased 
likelihood of being hospitalized [64]. Therefore, the discrepancies between sexes called for more 
attention from health care providers and scholars. Table 2.1 describes characteristics of studies 
that investigated the association between sex and hospital utilization in patients living with 
COPD. 
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Table 2.1 Characteristics of studies to investigate the association between sex and hospital usage 
in patients living with COPD 
First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
de Torres JP 
70
 
(2005) 
Spain 
Case-control  N=106, 53 FEV1-
matched men and 
women with COPD 
attending clinic at 
Hospital Universitario 
Ntra Sra de Candelaria in 
Spain.  
Inclusion criteria: the 
subject had smoked ≥10 
pack-years and had a 
postbrochodilator 
FEV1/FVC of <0.7 after 
400 µg of inhaled 
albuterol. 
No statistically significant 
difference observed in the 
rates of hospitalization 
between sex (p=0.101). 
Watson L 
71
 
(2004) 
USA, 
Canada, 
France, 
Italy, 
Germany, 
The 
Netherlands, 
Spain and 
the UK 
Cross 
sectional  
N= 3,265 
Source population: 
survey (hospitals and 
emergency room) 
Inclusion criteria:  
patients were at least 45 
years old, with a reported 
physician diagnosis of 
COPD, chronic 
bronchitis or 
emphysema, or with 
symptoms of chronic 
bronchitis (defined as 
persistent cough with 
sputum from the chest 
for the last two years or 
more). 
 
There were no differences in 
the 
risk of hospitalization 
between sexes 
(OR= 0.81, 95%CI: 
0.64,1.03) 
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First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
Anthonisen 
NR 
51
 
(2002) 
Manitoba 
Canada 
Prospective 
cohort 
N=5,887 
Participants had annual 
clinic visits for 5 years 
that included 
questionnaires on 
smoking, use of 
prescription drugs, 
serious illness, 
hospitalizations, and 
physician visits. 
Hospitalization was found to 
be associated with female sex  
Menec VH 
72
 
(2005) 
Manitoba, 
Canada 
Cross 
sectional 
N=7,678 
Source population: 
Administrative data 
Inclusion criteria: adults 
65 years or older and 
died in Manitoba, 
Canada. 
There were no differences in 
the 
risk of hospitalization 
between sexes (OR=1.01, 
95%CI: 0.92, 1.12 in the last 
30 days of life; OR=1.01, 
95%CI=0.91, 1.12 in the last 
180 days of life) 
 
 
Age 
Age has been proven to be a significant determinant of hospital and ICU utilization. In Canada, 
statistics showed that, for the period from 1984 to 1993, COPD was the fourth-ranked cause of 
hospitalization among men aged greater than 65 years of age; and among women aged greater 
than 65 years, COPD was the sixth most frequent cause of hospitalization during the same period 
[5]. A previous Canadian study in 2002 claimed that COPD was a leading cause of 
hospitalization amongst adults, particularly in older populations [18]. According to a Canadian 
study from Lacasse and colleagues in 1999, the age-specific hospitalization rate increased among 
the elderly (aged 65 years and more), particularly in those aged 75 years and older [8]. Data also 
showed that the odds of lengthier in-hospital stay were associated with increasing age [8]. Wolff 
and colleagues, in 2002, also found an increased rate of hospitalizations with increasing age, 
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rising from 21.3 per 1,000 beneficiaries between 65 and 69 years of age to 82.1 per 1,000 
beneficiaries aged 85 years and older in the United States [64]. In marked contrast, some studies 
showed opposite findings in the relationship between age and hospitalization. In Amsterdam, 
according to Pot and colleagues, aging was a positive predictor of hospitalization in 2009 [47], 
which was in contrast to findings reported by Menec et al. [72].  
 
When it comes to ICU use, previous studies reported inconsistent results in terms of the 
association between age and ICU admission. According to Seferian et al., in 2008, the number of 
ICU admissions was found to increase with age with the highest number in the very elderly in 
Minnesota [62]. However, building on the work of Menec and colleagues, in 2005, the odds of 
being admitted to intensive care settings decreased with patient’s age in the province of 
Manitoba, Canada [72]. Table 2.2 describes characteristics of studies that investigated the 
association between age and hospital utilization in the COPD population. 
 
Table 2.2 Characteristics of studies to investigate the association between age and hospital usage 
in patients living with COPD 
First author 
reference # 
(Year 
published) 
Location 
Study design Study 
population 
(Sample size) 
Outcome & strength of association 
  
 
21 
Pot AM 
47
 
(2009) 
Amsterdam 
Retrospective 
case-control 
N=3,107  
The sample 
was recruited in 
1992 for the 
NESTOR-study 
on ling 
Arrangements 
and Social 
Networks of 
older adults. 
Inclusion 
criteria: adults 
aged 55 years 
or older. 
 
Age was a positive predictor for 
hospitalizations (logistic regression 
coefficient=0.007, p<0.0001) 
Menec VH 
72
 
(2005) 
Manitoba, 
Canada 
Cross 
sectional 
N=7,678 
Source 
population: 
Administrative 
data 
Inclusion 
criteria: adults 
65 years or 
older and died 
in Manitoba, 
Canada 
Individuals 85 years old or older had 
lower odds of being admitted to an 
ICU than did individuals 65–74 years 
old (OR=0.23 (0.18, 0.29) in the last 
30 days, 0.24 (0.19, 0.30) in the last 
180 days). Individuals 75-84 years old 
had increased odds of being 
hospitalized (1.20 (1.06, 1.37) in the 
last 30 days 1.22 (1.07, 1.40) in the last 
180 days)but lower odds of being 
admitted to an ICU than did 
individuals 65-74 years old (0.74 (0.60, 
0.90)in the last 30 days 0.71 (0.59, 
0.85) in the last 180 days) 
Seferian EG 
62
 
(2006) 
Minnesota 
Retrospective 
cohort 
N=818 
Source 
population: 
ICU 
Inclusion 
criteria: 
subjects aged 
18 years or 
older. 
An increasing proportion of those in 
the elderly age groups being admitted 
to the ICU for monitoring only, from 
24% in the 65- to 74-yrs-old age group 
to 36.4% in those aged 85 years and 
older 
Residents greater than 85 years old 
were 3.75 times as likely (p < 0.001) to 
be admitted to the ICU  
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Comorbidity 
 
Comorbidity is a common feature of the population with critical illness. Patients with COPD 
typically have comorbid conditions, such as muscle wasting, diabetes, renal failure, 
cardiovascular disease (CVD), depression, reduced fat-free mass, osteopenia, and chronic 
infections [73]. Among all the common chronic conditions, previous literature has confirmed that 
cardiovascular disease accounted for the highest proportion of comorbid conditions in 
individuals with severe COPD [73]. 
 
These comorbid conditions were recognized as contributors to hospitalization in patients with 
COPD residing in British Columbia, Canada in 2008 [67]. Furthermore, cardiovascular disease 
was recognized as a contributor of hospitalization of COPD patients, from 1980 to 1995, 
followed by accidental fall and stroke, as reported in an earlier Canadian study [8]. Based on the 
work by Wong and colleagues, in 2008, an increasing number of comorbidities increased the risk 
of hospital readmission in the province of British Columbia, Canada [67]. Similar results were 
also reported from a case control study conducted in Amsterdam in 2009; it confirmed that 
multiple comorbid conditions were positively associated with acute care utilization [47]. 
Moreover, comorbidity also influenced the types of care delivered and the frequency of ICU 
admissions [64]. According to Wolff and colleagues, in 2002, subjects with more than four 
comorbid conditions were found to be 99-times more likely to be admitted to hospital than those 
without any co-existing condition in the United States [64]. Not unexpectedly, patients with 
multiple comorbid conditions were high utilizers of medical care, as indicated by a U.S. study in 
2004 [74]. Based on the study conducted in Minnesota from Seferian and colleagues, in 2006, 
subjects with one or more comorbid illnesses were more likely to receive ICU care in the last 6 
months of life than subjects without any complications [62]. Data also showed that residents with 
3 to 4 comorbid conditions were found to have 95-times higher rate of ICU visit compared with 
individuals without any comorbidity [62]. Table 2.3 describes characteristics of studies that 
investigated the association between comorbidity and hospital utilization in the COPD 
population. 
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Table 2.3 Characteristics of studies to investigate the association between comorbidity and 
hospital usage in patients living with COPD 
First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
Pot AM
 47
 
(2009) 
Amsterdam 
Retrospective N=3,107  
The sample was recruited 
in 1992 for the NESTOR-
study on ling 
Arrangements and Social 
Networks of older adults. 
Inclusion criteria: adults 
aged 55 years or older. 
Increasing number of 
comorbid illness was a 
positive predictor for 
hospitalizations (logistic 
regression 
coefficient=0.151, 
p<0.0001) 
Wong AW 
67
 
(2008) 
British 
Columbia, 
Canada 
Retrospective 
cohort  
N= 109 admissions 
Source population: 
administrative data. 
Inclusion criteria: patients 
aged 35 years or older, had 
a diagnosis of COPD, with 
a FEV1 of less than 70% of 
the predicted value, with a 
total lung capacity of 
greater than 80% of the 
predicted value 
Exclusion criteria: patients 
with a FEV1 increased to 
80% of the predicted 
value, or reported a use of 
inhaled bronchodilator 
product, or they had other 
diseases which was serious 
enough to influence their 
quality of life or clinical 
course (i.e. cancer, left 
ventricular failure, stroke, 
etc.) 
Hospital readmission was 
associated with the number 
of comorbid conditions 
(OR= 1.47, 95%CI: 
1.10,1.97) 
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First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
Seferian EG
 
62
 
(2006) 
Minnesota 
Retrospective 
cohort 
N=818 
Source population: ICU 
Inclusion criteria: subjects 
aged 18 years or older. 
Subjects with one or more 
comorbid illnesses were 
more likely to receive 
ICU care in the last 6 
months of life than 
subjects without any 
complications. Data 
also showed that 
residents with 3 to 4 
comorbid conditions 
were found to have 95-
times higher rate of ICU 
visit compared with 
individuals without any 
comorbidity  
 
2.5.3.2 Lung Cancer  
Sex 
Based on evidence from the scientific literature, sex played a significant role in determining the 
treatment decision among the lung cancer population. For example, a cross-sectional U.S. study, 
in 1999, showed that male patients were more likely to accept aggressive interventions in the 
hospitals than their female counterparts [75]. Women’s past experience as a caregiver for their 
sick relatives might influence their attitudes towards aggressive care, such as aggressive 
interventions in the ICUs, resulting in a higher denial rate, which was also suggested by a 
Canadian study in 2007 examining sex-difference in the care delivery [68].  
 
Regarding the use of hospital services, Fowler and colleagues observed that, among all the 
subjects admitted to hospitals, more women than men were observed. Furthermore, female 
patients also spent longer with each hospitalization than their male counterparts [68]. The higher 
risk of frequent hospitalizations in females was found to be associated with the deteriorating 
pulmonary functions. According to Prescott and colleagues, females were more susceptible than 
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males to the effects of smoking with regard to development of lung diseases [67]. In marked 
contrast, Holmquist and colleagues, in 2008, found that the rate of lung cancer-related 
hospitalizations were highest in males 65 years and older in the United States [53]. 
 
Sex was also found to influence the provision of critical care services. An earlier Canadian report 
in 2007 suggested that fewer women than men were admitted to ICU even though they were 
significantly more likely to be admitted to hospitals [68].  Fowler et al. also reported a reduced 
likelihood of receiving mechanical ventilation in females in the ICU settings despite suffering 
the same degree of pulmonary deterioration at the time of ICU admission [68]. Moreover, 
women who received ICU services had a slightly shorter duration than men even though it was 
not statistically significant. This was also confirmed by Valentin et al. in Austria and Romo et al. 
in Belgium [76, 77]; males with lung cancer were more likely to seek health care resources and 
to undergo more invasive therapies than their female counterparts. However, according to a U.S. 
report from Sharma and colleagues, ICU use did not differ substantially by sex in 2008 [59]. 
Previous studies suggested that there were still considerable gaps in our knowledge about the 
factors, including sex, which may affect LOS in hospital or in ICU. Table 2.4 describes 
characteristics of studies that investigated the association between sex and hospital utilization in 
the lung cancer population. 
 
Table 2.4 Characteristics of studies to investigate the association between sex and hospital usage 
in patients living with lung cancer 
First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
Blackhall 
LJ 
75
  
(1999) 
Los 
Angeles 
USA 
Cross-
sectional  
N=800 
Source population: survey. 
Inclusion criteria: 
individuals aged 65 years 
or greater and residing in 
Los Angeles County. 
Male patients were more likely 
to accept aggressive 
interventions in the hospitals 
than their female counterparts 
(OR=0.5, 95%CI: 0.3, 0.7) 
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First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
Romo H 
77
 
(2004) 
Belgium 
Retrospective 
population-
based cohort  
N=4,420 
Source population: ICU 
The odds of critical care use 
declined with increasing age 
(OR=0.31, 95%CI: 0.31-0.32, 
comparing patients more than 
90 years old with those 68-70 
years old) 
Sharma G 
59
 
(2008) 
USA 
Retrospective 
population-
based cohort  
N= 45,627 
Source population: the 
National Cancer Institute’s 
Surveillance, 
Epidemiology, and End 
Results (SEER) registries. 
Inclusion criteria: 
individuals aged 65 years 
and above. 
 
ICU use didn’t differ 
substantially by sex 
(OR=0.965, 95%CI: 0.918–
1.015) 
 
 
Age 
Increasing age was strongly associated with increasing rates of cancer as indicated by previous 
research [78]. Data showed that men and women aged 65 years or above had a risk eleven times 
greater than those aged less than 65 years [78]. In addition, aging was also associated with 
increased vulnerability to health problems and impaired physical functioning.   
 
Elderly patients, however, were found to use not as much standard care services as their younger 
counterparts [74, 79-82]. According to a report conducted in Belgium from Berghmans and 
colleagues, in 2002, among patients living with non-small-cell lung cancer, one out of five 
patients aged 75 years or greater did not receive the standard treatment [82].  This finding was 
also in line with the work by Townsley and colleagues in 2005; they found that the odds of a 
patient 70 years of age or older receiving any cancer treatment were just half of that of a patient 
under age 70 years in the province of Ontario, Canada [80]. One possible explanation was the 
changes in the tolerance to the standard treatment, which influences the safety and effectiveness 
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of therapy in this population. They also observed a decreased likelihood of having a clinical trial 
discussion with the cancer specialist among the elderly [80].  
 
Age was also found to influence the provision of critical care services. Based on a U.S. study in 
2008, the odds of critical care use declined substantially with increasing age [59].  According to 
Sharma and colleagues, ICU use was significantly associated with younger age while individuals 
less than 85 years old had the least use of intensive care services [59]. This result was also 
confirmed by work from Iwashyna and colleagues in 2004 who found that increasing age 
decreased the odds of ICU admission, with the lowest odds observed in the oldest age group 
(>90 years of age) in the United States [74]. However, these results were in marked contrast with 
the finding from Craig et al. in 2004, which showed a steadily increasing use of care services in 
ICUs among patients aged 65 years and above in the United States [81]. Iwashyna and 
colleagues also observed a lowest rate of ICU admission for the very old patients (aged 85 years 
and above) [74]. Age was also found to influence patterns of ICU demands and expenditures. 
Some studies made projections that ICU care consumption would increase in the next several 
decades as a result of an aging population [62].  This justified that further evidence was needed 
to better examine the relationship between age and hospitalization among lung cancer patients. 
Table 2.5 describes characteristics of studies that investigated the association between age and 
hospital utilization in the lung cancer population. 
 
Table 2.5 Characteristics of studies to investigate the association between age and hospital usage 
in patients living with lung cancer 
First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
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First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
Townsley 
C
80
  
(2005) 
Ontario 
Canada 
Retrospective 
Chart review 
  
N=1,505 
Source population: 
administrative data. 
Inclusion criteria: 
individuals over the age 
of 35 years with lung, 
breast, colorectal 
cancer. 
The odds of a patient 70 years of 
age or greater receiving any 
cancer treatment were half of that 
of a patient aged less than 70 
years (OR=0.50, 95%CI= 0.33-
0.76) 
Berghmans 
T
82
 
(2002) 
Belgium 
Prospective 
cohort study 
N=604 
Source population: 
cancer hospital. 
Inclusion criteria: 
patients aged 75 years 
and above and 
diagnosed with lung 
cancer; had a normal 
white blood cell 
(>4,000/mm
3
) and 
platelet (> 
100,000/mm
3
) counts. 
Exclusion criteria: 
recent myocardial 
infarction or cardiac 
arrhythmia requiring 
treatment, uncontrolled 
infectious disease, 
medical or 
psychological factors 
preventing adherence to 
the treatment schedule, 
prior treatments (i.e. 
chemotherapy, surgery 
or radiotherapy).    
Among patients living with non-
small-cell lung cancer, data 
showed that 20% of patients 
aged 75 years of age or 
greater didn’t receive the 
standard treatment. 
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Comorbidity 
Earlier reports suggested that comorbidity was highly prevalent in the lung cancer population 
and the majority of those with lung cancer have at least one comorbid condition [83]. According 
to a Spanish study, in 2002, nearly three quarters of them presented with one or more 
comorbidities; among those with multiple comorbid conditions, half of the subjects living with 
COPD. It also found that older patients showed a higher risk in developing comorbid illness [83]. 
This finding was in line with the work by Westert and colleagues in 2001; they also reported a 
higher prevalence observed in elderly women in the United Kingdom [84].  
 
Moreover, comorbidity plays an important role in the delivery of hospital services.  Based on 
evidence from the scientific literature, comorbidity was related with higher mortality and 
consumption of in-patient hospital and ICU resources [55, 59, 63, 74, 81]. According to two 
earlier Canadian reports, multiple comorbid conditions were found to be a positive predictor of 
ICU admission [55, 63]. This result was in line with the work by Iwashyna and colleagues, in 
2004, where over half of the American medical beneficiaries being managed in the intensive care 
settings living with multiple chronic illnesses [74]. Furthermore, data also showed that patients 
living with comorbid illnesses were reported as repeated users for intensive care services [74]. 
Consistent result was also reported from a USA study in 2004, where the increasing number of 
comorbid conditions increased the odds of ICU admission by 1.14 times [81]. Table 2.6 
describes characteristics of studies that investigated the association between comorbidity and 
hospital utilization in the lung cancer population. 
 
Table 2.6 Characteristics of studies to investigate the association between comorbidity and 
hospital usage in patients living with lung cancer  
First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
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First author 
reference # 
(Year 
published) 
Location 
Study design Study population 
(Sample size) 
Outcome & strength of 
association 
Barbera L
55
 
(2006) 
Ontario 
Canada 
Retrospective 
population-
based cohort  
N=21,323 
Source population: 
administrative data. 
Comorbidity significantly 
influenced the likelihood of 
being admitted to ICUs 
(adjusted OR=1.606, 95%CI: 
1.394-1.853) 
Sharma G 
59
 
(2008) 
USA 
Retrospective 
population-
based cohort  
N= 45,627 
Source population: the 
National Cancer 
Institute’s Surveillance, 
Epidemiology, and End 
Results (SEER) 
registries. 
Inclusion criteria: 
individuals aged 65 years 
and above. 
Subjects with more comorbid 
illnesses were more likely to 
receive ICU care in the last six 
months of life (OR=1.622, 
95%CI: 1.525–1.7425) 
Earle CC
81
  
(2004) 
Boston 
USA 
Retrospective 
cohort 
N=28,777 
Source population: the 
National Cancer 
Institute’s Surveillance, 
Epidemiology, and End 
Results (SEER) registries 
and Centers for Medicare 
and Medicaid Services 
Medicare claims data. 
Inclusion criteria: 
individuals aged 65 years 
and above and died from 
lung, breast, colorectal, 
and other gastrointestinal 
cancers. 
Increasing number of comorbid 
conditions increased the odds of 
ICU admission (adjusted 
OR=1.14, 95%CI: 1.06-1.23) 
 
2.6 Summary 
Chronic respiratory illnesses, such as COPD and lung cancer, represent an increasing burden in 
terms of morbidity and mortality across the world. However, the experience of those dying from 
these diseases was poorly understood, particularly for the population of COPD patients, who 
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frequently attended aggressive care settings, died in hospitals, and had unmet personal 
preferences at the end of life.  Many factors affecting the hospital utilizations in patients dying 
from COPD or lung cancer have been proposed, including personal characteristics and overall 
health status. 
 
 
Chapter 3: METHODS 
3.1 Study design 
A retrospective study was conducted to compare the difference in hospitalization trends between 
decedents with COPD and decedents with lung cancer using administrative health data. 
Information on hospitalization in the six months prior to death for each person dying from COPD 
or lung cancer was collected from 1997 to 2006. We included three persons who died on January 
1
st
, 2007, with those who died in 2006 for the analysis as their time contribution would be 
entirely from 2006. The primary outcome of interest was the hospitalization indicators, including 
LOS (total LOS in hospitals and average LOS per hospitalization) and total number of 
hospitalizations near the end of life.  
 
3.2 Study population 
The study sample consisted of all individuals who died of COPD or Lung cancer between 1997 
and 2006 in Saskatchewan, Canada. Data in this study was obtained from Saskatchewan Health, 
which provided health care services coverage to approximately 99% of residents. Persons not 
covered included those covered by the federal government, namely, Royal Canadian Mounted 
Police, Canadian Forces members, and inmates of federal penitentiaries. In addition, Registered 
Indians were also excluded from this study because the federal government covered prescription 
drug costs for this group. We excluded individuals who were not covered under Saskatchewan 
Health at the time of the study. Finally, the study sample consisted of 7,114 people.  
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The end-of-life period referred to the last six months of life, and was measured by working 
backwards from date of the death recorded by Saskatchewan Health. The underlying cause of 
death (UCOD) was utilized to select individuals who died of COPD or lung cancer over the 10-
year study period. The cause of death of all eligible subjects was obtained from the Vital 
Statistics Registry. The causes of death recorded on this form were keyed in electronically and an 
algorithm was applied to determine the underlying cause of death in accordance with WHO 
criteria.  
 
3.3 Overview of Data Sources 
Data in this study was obtained from Saskatchewan Health. There were a number of health 
databases maintained by Saskatchewan Health. Each insured individual had a unique identifier 
that could be used to link personal health records from each of the databases. Prior to receiving 
data from Saskatchewan Health, the unique identifier was de-identified and was replaced with a 
unique encrypted number. The databases we used from Saskatchewan Health included the 
population registry database, hospital service database, institutional supportive care database, 
and vital statistics database. 
 
The population registry collected data on sex, year of birth, residence information, and dates of 
health care coverage. The hospital service file included dates of admission and discharge, 
diagnoses and diagnoses types, and procedures of interest undertaken during hospitalization. The 
vital statistics file contained information on the date of death, underlying cause of death (UCOD) 
and multiple cause of death (MCOD) as well as the location of death, such as in-hospital vs. out-
of-hospital death. Finally, the institutional supportive care database had information on the type 
of supportive care services and number of hours for each type of service. 
 
We used data that spanned a period of ten years. As such, the data was very comprehensive 
compared to studies that spanned fewer periods. The study population was also representative of 
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residents of Saskatchewan who were covered under Saskatchewan Health given that it was 
nearly a complete sample.  
 
3.4 Theoretical Framework 
The behavioural model of health care utilization, developed by Andersen, Aday and others, was 
recognized as one of the most commonly used conceptual frameworks for examining factors 
associated with patient utilization of care [85].  
 
This conceptual framework successfully integrates a wide range of variables (health policy, 
health hospitalization and characteristics of target population) associated with care-seeking 
decisions. By doing this, health care professionals and policy makers are able to identify the 
reasons for differences in utilization of care and establish programs and policies in appropriate 
care seeking. In addition, this conceptual framework could be used to guide research on health 
care utilization. It has been used by 19 studies to examine the accessibility to end-of-life care 
services among people with terminal illness. Figure 1 shows the relationship between the main 
components of the framework. 
  
 
34 
 
Figure 3. 1 Access to Medical Care 
 
Health Policy: According to Aday and Andersen, health policy was described as the starting 
point of the access to health care resources, which included hospitals and ICUs [85]. As shown in 
this diagram, health policy consisted of financing, education, manpower and health care 
organization programs. In order to improve access to health care, especially among socially 
disadvantaged populations, policy-makers should establish policies suited to their financial and 
educational needs. 
 
Characteristics of the Health Care Delivery System: The health care delivery system seeks to 
provide high quality patient health care in the treatment and prevention of human illness. There 
are two key components of health care delivery system--- resources and organization. Resources 
consist of the volume and the distribution of medical resources in an area; while organization is 
the structure of the system. In addition, the characteristics of the health care delivery system are 
interrelated and interact with each other. The resources component encompasses a wide range of 
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health professionals, educational materials and medical equipment; while organization is 
described as the manner in which health care providers and institutions are properly coordinated 
and managed.  
 
Characteristics of the Population at Risk: The characteristics of the population at risk 
encompass predisposing, enabling, and need components. The predisposing component includes 
factors that exist prior to the onset of the disease, such as age, sex, race, religion. The enabling 
component refers to a means that allows individuals to use health services. It includes such 
things as individual’s income and his or her health care coverage. The need component is 
described as disease level. It decides directly whether the patient needs care and protection, and 
evaluates how much care should be provided to the patient. 
 
Utilization of Health Services: The utilization of health services is described in terms of type, 
site, purpose, and the time interval involved. The type of utilization encompasses a wide range of 
services provided by a wide variety of health professionals, including physician, dentist, 
pharmacist, etc. The site of the utilization refers to the place where the health services were 
received: ICU, emergency room, inpatient department, etc. The purpose of utilization is 
described as preventive, illness-related, or custodial care. Preventive care is characterized as 
prevention of a disease before it begins, including immunization and screening. Illness-related 
care is described in terms of acute and chronic illnesses. Curative care has been provided to 
patients living with acute diseases, such as flu and fever. In regards to chronic illness, long-term 
care will be given to patients with irreversible illness (e.g. COPD and heart failure). The time 
interval required for a visit is described in terms of contact, volume, and continuity measures. 
Contact refers to whether a person uses the health care services in a given period of time. 
Volume refers to the number of visits by a person in a given period of time. Continuity is 
concerned with the quality of care a person received in a given period of time. It measures the 
degree of a patient’s experience of a continuous caring relationship with the health care system. 
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Consumer Satisfaction: Consumer satisfaction refers to an individual’s attitude towards the 
health care system. It also measures how efficiently the health services are managed and how 
promptly services are provided. It has been recognized as a key indicator within health care 
services. 
 
By using this conceptual model, we are able to examine the factors predicting the probability of 
use and amount of use of hospital services among the COPD population. Additionally, by linking 
data from Saskatchewan Health’s hospital service records, this study is able to explore the 
factors that influence the differences between sexes. For example, whether the disparity between 
sexes could be predominantly explained by the characteristics of the target population (such as 
age and sex) or the characteristics of the utilization of health services (for example, time spent in 
ICU). However, we are not able to investigate every aspect of the conceptual model due to the 
limited information from Saskatchewan Health, which results in a reduced internal validity of the 
study.  
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The variables that were analyzed in this study were presented in Figure 2 (Characteristics of 
Health Services Utilization) and Figure 3 (Individual Determinants of Health Hospitalization) 
 
Figure 3. 2 Characteristics of Health Service Utilization 
 
Figure 3. 3 Individual Determinants of Health Service Utilization 
 
Characteristics of health hospitalization describe the type of health service provided to 
individuals, the purpose of the utilization, and the unit of analysis. 
With respect to type of health service, we define it in this study as the place (ICU or in-hospital 
departments) where the service was received by an individual. In the current study, the purpose 
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of service refers to tertiary care, which provides stabilization for long-term irreversible diseases, 
for example, COPD and lung cancer. Another characteristic that was studied is the unit of 
analysis. We defined this variable as: 
1) Time spent in hospital prior to death  
2) Number of admissions  
 
In addition to the characteristics of the health service, we were also interested in the individual 
determinants of hospitalization that allows health professionals to determine the health care 
offered from the health facilities. The figure above describes a sequence of factors that 
contributes to decisions made to seek health care. 
According to the model, the use of health service is based on: 
1) The predisposition of the patient to seek service 
2) The enabling conditions that allow a patient to seek health resources 
3) The patient’s illness level 
In this analysis, the predisposing factors will be measured as age and sex. Although these 
characteristics are not directly related to the health utilization, previous literature suggested that 
female patients, particularly those of older age, were more likely to use health services. 
 
With regards to the enabling factors, it will be characterized as the rural-urban nature of the 
community in which the individual lives. It will be measured as the percentage of the population 
that is urban or rural within the province of Saskatchewan. The enabling variable is important in 
this analysis because it links to how medicine is practiced in the community that influences the 
health seeking behaviour of the individuals living in the community. 
Illness level is believed to be the most immediate cause of the utilization of care. Measures of 
illness level include: 
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1) Diagnosis of the disease (COPD and lung cancer) 
2) Comorbidities  
 
3.5 Operational Definitions 
3.5.1 COPD and lung cancer 
COPD and lung cancer were defined according to the International Classification of Diseases 
(ICD) coding following the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines, which was also consistent with that used in the US National Center for Health 
Statistics COPD Surveillance Summary 1971–2000 [55].  
 
The information on COPD, lung cancer, and causes of death were coded and tabulated according 
to both the ninth and the tenth revision of the International Classification of Diseases [82] as the 
study period crossed the transition period between ICD-9 and 10 coding.  
 
Table 3.1 shows the method of ICD coding. 
DISEASE ICD-9 ICD-10 
COPD 491.x, 492.x, 493.2, 496.x J44.x 
Lung Cancer 162.x, 195.1, 165.x C34.x 
 
3.5.2 Hospitalization (includes any in-patient days) in the six months prior to death 
Data was retrieved from the hospital service database; and the reason for hospitalization is 
identified by “primary diagnosis.” In order to avoid double counting from inter-hospital transfers, 
we counted a patient who was readmitted to another hospital on the same day of discharging 
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from an existing hospital as having one transfer, and combined two hospitalizations rather than 
counting it as a second admission. 
Hospitalization was considered as Total LOS in hospitals, Average LOS per hospitalization, and 
total number of hospitalizations in the six months prior to death for each disease group (COPD 
and lung cancer)  
Since the assumptions of normality were not met, the number of hospitalizations were classified 
as ≥2 visits or <2 visits during the last 6 months of life, and both of the total LOS in hospitals 
and average LOS per hospitalization were categorized as >7 days or ≤7days as per a previous 
study [50].  
 
3.5.3 Hospitalization in one month prior to death (includes any in-patient days)  
Hospitalization in the past month referred to hospital stays in the 30 days prior to death. Most 
patients with chronic respiratory disease remain quite functional until approximately five to six 
months prior to their deaths [87]. During one to two months before their deaths, their health 
status tends to decline rapidly. In Teno's study in 2003, more than 50 percent of lung cancer 
patients reported that they had difficulty getting out of a bed or chair one month prior to death 
[88]. Previous literature also found a dramatic increase in the proportion of people admitted to 
ICU in the mother before they died over the last decade [89]. Thus, it was important to 
investigate the trends of hospitalization among patients with terminal respiratory disease one 
month prior to their deaths. This was considered as total LOS in hospitals and average LOS in 
hospitals in one month prior to death for each disease group (COPD and lung cancer). 
 
3.5.5 Independent Variables of Interest 
The independent variables of primary interest were disease status (COPD and lung cancer), age 
group (≤59 years, 60-69 years, 70-79 years, 80-89 years and ≥90 years), sex (male and female), 
and comorbid conditions (0-1 condition and ≥2 conditions). Other variables that were also 
included in the analysis were residence (≥300,000 population in their communities, 10,000-
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299,999 population in their communities, and <10,000 population in their communities), location 
of death (in hospital and outside hospital), marital status (married/ common law, never married, 
separated/ divorced, and widowed), institutional supportive care services (yes and no), transfers 
between institutional supportive care facilities (yes and no), and number of transfers between 
institutional supportive care facilities.  
 
3.6 Statistical analysis 
All data analysis in this study were conducted using SPSS (19.0). All statistical tests were two 
tailed, and α was set at 0.05 to define statistical significance.  
 
3.6.1 Baseline Characteristics 
Throughout the analysis, the variable of primary interest was disease status (COPD vs. lung 
cancer). Initially, baseline characteristics of the study population were described and compared 
by disease group. Continuous variables were expressed as means and standard deviations (SD). 
Statistical comparison of the differences between disease groups was completed using the 
independent samples t-test. Descriptive analyses using categorical variables were presented as 
frequencies and proportions. For categorical variables, statistical comparisons between groups 
were completed using the chi-squared tests. Characteristics of patients with COPD or lung cancer 
were compared to determine whether differences existed in age distribution, sex, and co-
morbidities.  
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3.6.2 Analysis for each Research Question  
1: How do indicators of hospitalization in the six months prior to death compare between 
patients with a diagnosis of COPD and those with a diagnosis of lung cancer?  
This analysis was primarily descriptive. The independent variable of primary interest was the 
disease status (COPD and lung cancer). The outcome was hospitalization, which was expressed 
as: 
1) Total LOS in hospitals in the six months prior to death for each disease group (COPD and 
lung cancer); 
2) Total LOS in hospitals in one month prior to death for each disease group (COPD and lung 
cancer);  
3) Average LOS per hospitalization in the six months prior to death for each disease group 
(COPD and lung cancer); 
4) Average LOS per hospitalization in one month prior to death for each disease group (COPD 
and lung cancer);  
5) Number of hospitalizations in the six months prior to death for each disease group (COPD 
and lung cancer); 
6) Number of hospitalizations in the one month prior to death for each disease group (COPD 
and lung cancer); 
 
Statistical comparisons of the differences between COPD and lung cancer groups were 
completed using the independent samples t-tests if the assumptions were met and the Mann-
Whitney test if the assumptions were not met.  
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2: Is there an association between the following independent variables and hospitalization 
among the target population and do they modify the effect of diagnostic group? 
(a) age; (b) comorbidity; (c) sex 
To investigate this research question, first, the chi square test was performed to determine the 
univariate association between age group, comorbidity, and sex with hospitalization. Following 
this the association was assessed using a univariate logistic regression model. Variable selection 
followed that of Hosmer [88]. Variables with p<0.25 in the univariate analysis were the 
candidate variables for a full multivariate model. Variables in the full multivariate model with 
p<0.05 were included in the reduced model. Following this, assessment of confounding took 
place. Variables in the full multivariate model with p>0.05 were added to the reduced model to 
evaluate the confounding. In order to assess the presence of confounding, the crude beta 
coefficient (without controlling for confounding) was compared with the beta coefficient 
adjusted for the potential confounder. If the beta coefficient had changed significantly 
(approximately 15% or more), then there was evidence of confounding and that variable was 
retained in the final main effect model. The strength of associations was presented by odds ratios 
and their 95% confidence intervals for categorical variables. Disease status remained in all 
models due to its role as a primary variable. Throughout the analysis, disease status, age, sex, 
and comorbid condition were included in the models. 
 
In order to test whether sex was an effect modifier in the association between disease group and 
LOS, two methods were performed.  
(1) Stratified analysis: 
First, stratified analysis was performed. Stratification occurred by sex. The odds ratio (ORMale 
and ORFemale) was calculated from the 2*2 tables shown below. 
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Stratum1 (Male) 
 <7 days >7 days 
COPD A1 B1 
Lung 
Cancer 
C1 D1 
ORMale= 
 
Stratum2 (Female) 
 <7 days >7 days 
COPD A2 B2 
Lung 
Cancer 
C2 D2 
ORFemale= 
 
If ORMale ≠ ORFemale, it suggested that the association between disease status and hospitalization 
was dependant on sex, then an interaction between sex and disease status could be said to exist. 
 
(2) Likelihood Ratio Test: 
Second, I performed the likelihood ratio test to investigate this research question. An interaction 
term (sex*disease group) was added to the final main effect model containing all the main effects. 
If the interaction was statistically significant it would be retained in the final multivariate model. 
The final model included the main effects and significant interactions. The interaction effect was 
described through the linear combination of effects. The strength of associations was presented 
by odds ratios and their 95% confidence intervals.  
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Other interactions of interest to be tested were comorbidity*disease group and age*disease group. 
Assessments of interaction were the same as above. 
 
3. Does the pattern of hospitalization change over a 10 year period and are the associations 
between hospitalization and diagnostic group, age, sex, and comorbidity consistent over the 10 
year period? 
The independent variables of primary interest were the disease status (COPD and lung cancer) 
and calendar year. The outcome was hospitalization and was considered as described above.  
Initially, descriptive analyses examined hospitalization for each year (from 1997 to 2006) by 
disease group (COPD and lung cancer). Following this, multiple logistic regression was 
performed to consider the effect of year. For this analysis, calendar year was forced into the final 
model obtained from research question 2 as a main effect variable in order to investigate the 
trends of hospital service utilization (Total LOS in hospitals, Average LOS per hospitalization 
and number of hospitalizations) over the 10-year study period. Interaction between calendar year 
and disease group was assessed following the methods described above (stratified analysis and 
LR tests).  
 
3.7 Sample Size and Statistical Power 
3.7.1 Overall 
Statistical power was calculated using G power 3.1 software. Throughout the power calculations, 
alpha was 0.05 and power (1-beta) was determined as 80%. All tests were two-sided. 
 
3.7.2 Sample size for research question 1 
In order to investigate Research Question 1, the Chi-square test was considered. Based on the 
study conducted by Goodridge et al. [58], 433 died of lung cancer while 602 died of COPD. 
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Therefore, ratio of lung cancer over COPD was 0.72. Regarding the proportion of hospitalization 
in each group, 40% of the COPD patients spent more than 7 days in hospitals, while there were 
48.2% from those with lung cancer.  Using the Chi-square test, we would require 722 people 
with lung cancer and 519 people with COPD. 
 
3.7.3 Sample size for research question 2(a) 
Sample size for Research Question 2(a) is based on logistic regression. Based on the report from 
the Division of Health Care Statistics [90], the hospitalization rate ranged from 45 per 10,000 in 
1995 to 49 per 10,000 in 2004. The age associated odds ratio was 1.16 among lung cancer 
patients according to the report from McCarthy et al. [64]. Using logistic regression, we would 
require 1444 decedents in total. 
 
3.7.4 Sample size for research question 2(b) 
Sample size for Research Question 2(a) is based on logistic regression. Based on the report from 
the Division of Health Care Statistics [90], the hospitalization rate ranged from 45 per 10,000 in 
1995 to 49 per 10,000 in 2004.  The comorbidity associated odds ratio is 1.61 among lung cancer 
patients according to the report from Barbera et al. [91]. Using logistic regression, we would 
require 155 decedents in total. 
 
3.7.5 Sample size for research question 2(c) 
Sample size for Research Question 2(c) was based on logistic regression. Based on the report 
from the Division of Health Care Statistics [90], the hospitalization rate ranged from 45 per 
10,000 in 1995 to 49 per 10,000 in 2004. The sex associated odds ratio was 1.15 among lung 
cancer patients according to the report from Huang et al. [75]. Using logistic regression, we 
would require 6436 decedents in total. 
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3.7.6 Sample size for research question 3 
Sample size for Research Question 3 was based on logistic regression. Based on the report from 
the Baillargeon and colleagues, the calendar year associated odds ratio ranged from 0.74 to 0.84 
between 1999 and 2007. Using logistic regression, we would require the total population to be 
between 2,389 and 6,821. 
 
3.7.7 Summary of sample size 
In the dataset, there were 2,332 subjects who died of COPD and 4,782 who died of lung cancer 
resulting in a total of 7,114 subjects included in the current study. Based on the above 
calculations, the largest required sample size in total was 6,821. Since the dataset (7,114) in the 
current study was larger than the largest required sample size, the sample size calculations 
showed that the study has an adequate sample size to achieve the desired statistical power of 
80%. 
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Chapter 4: RESULTS 
4.1 Research Question 1 
How do indicators of hospitalization in the six months prior to death compare between 
patients with a diagnosis of COPD and those with a diagnosis of lung cancer?  
Table 4.1 presents the personal characteristics for the study population (N=7,114) for each factor 
of interest including age, sex, residence, comorbid condition, location of death, marital status, 
institutional supportive care services, transfers between institutional supportive care facilities, 
and number of transfers between institutional supportive care facilities, comparing COPD 
(NCOPD= 2,332) and lung cancer (NLung cancer= 4,782) group. It was observed that between the 
COPD and lung cancer population, there were statistically significant differences in terms of all 
personal characteristics except for residence. 
Table 4.1 Personal Characteristics of the study population overall and by disease group 
 Overall  
N=7114 
Lung Cancer 
N=4782 
COPD 
N=2332 
P-value * 
 N (%) N (%) N (%)  
Age      
    ≤59 years  659 (9.3) 610 (12.8) 49 (2.1) <0.0001 
    60-69 years 1427 (20.1) 1197 (25.0) 230 (14.2)  
    70-79 years 2471 (34.7) 1717 (35.9) 754 (32.3)  
    80-89 years 2430 (34.2) 1212 (25.3) 1218 (52.2)  
     ≥90 years 127 (1.8) 46 (1.0) 81 (3.5)  
Sex     
    Female 2822 (39.7) 1948 (40.7) 874 (37.5) 0.008 
    Male 4292 (60.3) 2834 (59.3) 1458 (62.5)  
Residence     
    ≥300,000 2498 (35.1) 1679 (35.1) 819 (35.1) 0.20 
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    (10,000- 299,999) 1270 (17.9) 828 (17.3) 442 (19.0)  
    <10,000 3346 (47.0) 2275 (47.6) 1071 (45.9)  
Comorbid Condition     
    0-1  2823 (39.7) 1974 (41.3) 849 (36.4) <0.0001 
    ≥2 4291 (60.3) 2808 (58.7) 1483 (63.6)  
Location of Death     
    Hospital 5526 (73.5) 3553 (74.3) 1673 (71.7) 0.02 
    Outside Hospital 1882 (26.5) 1223 (25.6) 659 (28.3)  
Marital Status     
    Married/ Common Law 3668 (51.6) 2655 (55.5) 1013 (43.4) <0.0001 
    Never Married  617 (8.7) 402 (8.4) 215 (9.2)  
    Separated/ Divorced 1663 (23.4) 1036 (21.7) 627 (26.9)  
    Widowed 1166 (16.4) 689 (14.4) 477 (20.5)  
Institutional Service     
    No (reference) 5285 (74.3) 3783 (79.1) 1502 (64.4) <0.0001 
    Yes  1829 (25.7) 999 (20.9) 830 (35.6)  
Transfer within Institution     
    No (reference) 6783 (95.3) 4630 (96.8) 2153 (92.3) <0.0001 
    Yes 331(4.7) 152 (3.2) 179 (7.7)  
Number of Transfers within Institution among 
those receiving Institutional Services 
   
    0 (reference) 1498 (21.1) 847 (17.7) 651 (17.9) 0.004 
    1 297 (4.2) 139 (2.9) 158 (6.8)  
    2 27 (0.4) 11 (0.2) 16 (0.7)  
    3 7 (0.1) 2 (0.04) 5 (0.2)  
*Comparing Lung Cancer with COPD group 
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The average age of death for the deceased COPD patient was 79.1 years (SD= 7.8 years) whereas 
the average age of death for the decedents with lung cancer was 71.9 years (SD= 10.2 years). 
Discrepancies between disease groups were observed for the age distribution, which was 
categorized into five groups: ≤59 years, 60-69 years, 70-79 years, 80-89 years and ≥90 years. It 
was observed that the proportion of COPD deaths increased with age except for ≥90 years. This 
pattern was not witnessed in the lung cancer group. Significant differences existed between 
sexes, with 59.3% of decedents with lung cancer being male, compared to 62.5% of decedents 
with COPD. Regarding the comorbidity, a higher proportion of decedents with COPD (63.6%) 
had multiple comorbid illnesses than those with lung cancer (59.3%). Decedents from COPD 
(71.7%) were less likely to die in hospital when compared with decedents from lung cancer 
(74.3%). Most of the study population were married or lived common law, with 55.5% observed 
in the lung cancer group and 43.4% in the COPD group. With regards to the difference in the 
distribution of institutional supportive care services, most of decedents (79.1%) from lung cancer 
did not receive it as compared to decedents from COPD (64.4%). The majority of decedents 
never had transfers between institutions. Among those receiving services in the supportive care 
institutions, a similar proportion of lung cancer (17.7%) and COPD (17.9%) subjects never had 
any transfers. A larger proportion of deceased COPD patients had one, two, and three transfers as 
compared with the decedents from lung cancer.   
 
Information on the hospital care utilization, including total LOS in hospitals, average LOS per 
hospitalization, number of hospitalizations, and ICU admission, are illustrated in Table 4.2. In 
the last month of life, decedents with lung cancer spent more time in hospital (mean=13.5 days, 
SD=16.1 days of total LOS) than decedents with COPD (mean=10.3 days, SD=13.7 days of total 
LOS). Similarly, decedents with lung cancer had longer stay per hospitalization (mean=14.4, 
SD=14.4 days of average LOS) than decedents with COPD (11.5 days, SD=12.2 days of average 
LOS). A higher proportion of subjects dying of COPD were admitted to ICU (4.3%). However, 
this proportion was significantly less among subjects dying of lung cancer (0.06%). 
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Similar trends were also witnessed in the last six months prior to death. Decedents with COPD 
spent on average, 24.0 days (SD=26.2 days) in hospital, compared to 26.6 days (SD=25.5 days) 
among those in the lung cancer population. The lung cancer group had a longer average hospital 
stay per visit (14.3 days, SD=18.5 days) when compared with their COPD counterparts (13.4 
days, SD=18.6 days). The proportion of ICU admission was higher for decedents from COPD 
(5.3%) than for decedents from lung cancer (2.9%).
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Table 4.2 Hospitalization in patients with COPD and Lung Cancer by disease group and length of time prior to death 
  1 Month    6 Month  
 Lung Cancer 
N=4782 
COPD 
N=2332 
Total 
N=7114 
 Lung Cancer 
N=4782 
COPD 
N=2332 
Total 
N=7114 
In-patient Hospitalization        
    Total LOS in Hospital        
      Mean Total LOS ±S.D. (days) 13.5±16.1 10.3±13.7
‡
 12.4±15.4  26.6±25.5 24.0±26.2
‡
 25.7±25.8 
      Median Total LOS (Minimum, 
Maximum) 
10 (0, 210) 7 (0, 210) 9 (0, 210)  20 (0, 183) 16 (0, 184) 18 (0, 184) 
      % with Total LOS ≤7 days 41.3 53.7 ‡ 45.3  20.6 28.8‡ 23.3 
      % with Total LOS >7 days 58.7 46.3
 ‡
 54.7  79.4 71.2
‡
 76.7 
    Average LOS per visit        
      Mean Average LOS per visit ±S.D. (days)  14.4±14.4 11.5±12.2
‡
 13.5±13.8  14.3±18.5 13.4±18.6
†
 14.0±18.5 
      Median Average LOS (Minimum, 
Maximum) 
7 (0, 180) 5 (0, 180) 6.5 (0, 180)  9 (0, 180) 8.5 (0, 180) 8.75 (0, 180) 
      % with Average LOS per visit ≤7 days 50.3 59.5‡ 53.3  40.8 43.8† 41.8 
      % with Average LOS per visit >7 days 49.7 40.5
‡
 46.7  59.2 56.2
†
 58.2 
    Number of Hospitalizations        
      % with 0 hospitalization 13.9 17.0
 ‡
 14.9  0.1 0.3
 
 0.2 
      % with 1 hospitalization 64.8 67.5
‡
 65.7  35.1 47.2 39.0 
      % with ≥2 hospitalizations 21.2 15.5‡ 19.4  64.8 62.6‡ 60.8 
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ICU Admission        
     % with an ICU Admission 0.06 4.3
‡
 1.5  1.7 5.3
‡
 2.9 
* P<0.10 comparing the Lung Cancer with the COPD group 
† P<0.05 comparing the Lung Cancer with the COPD group 
‡ P<0.01 comparing the Lung Cancer with the COPD group 
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Table 4.3 presents sex-specific hospital utilization for lung cancer, COPD and the general population in both one month and six 
months prior to death. It was observed that decedents with lung cancer were more likely to consume greater hospital services (total 
LOS in hospitals, average LOS per hospitalization and number of hospitalizations) and have less ICU admissions than their COPD 
counterparts in each sex group.   
 
Table 4.3 Hospitalization in patients with COPD and Lung Cancer by disease group and length of time prior to death stratified by sex 
   1 Month   6 Months  
  Lung Cancer COPD Total Lung Cancer COPD Total 
 Male        
    In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 13.3± 16.6 10.2± 11.7 12.2± 15.2 24.7± 23.6 23.5± 25.6 24.3± 24.3 
         % with Total LOS ≤7 days 41.7 52.4 43.5 21.8 28.7 24.1 
         % with Total LOS >7 days 58.3 47.6 54.7 78.2 71.3 75.9 
      Average LOS per visit       
         Mean Average LOS per visit ±S.D. (days) 14.0± 15.0 11.4± 10.8 13.1± 13.8 13.1± 16.7 13.0± 18.3 13.0± 17.3 
         % with Average LOS per visit ≤7 days 50.6 58.4 53.2 43.2 43.6 43.3 
         % with Average LOS per visit >7 days 49.4 41.6 46.8 56.8 56.4 56.7 
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      Number of Hospitalizations       
         % with 0-1 hospitalization 77.3 84.3 79.7 35.3 47.1 39.3 
         % with ≥2 hospitalizations 22.7 15.7 20.3 64.7 52.9 60.7 
   ICU Admission       
      % with an ICU Admission 2.2 3.9 2.2 2.0 4.7 2.9 
Female       
   In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 13.7± 15.3 10.4± 16.5 12.7± 15.7 29.2± 27.8 24.9± 27.3 27.9± 27.7 
         % with Total LOS ≤7 days 40.6 55.8 45.3 18.8 28.9 22.0 
         % with Total LOS >7 days 59.4 44.2 54.7 81.2 71.1 78.0 
      Average LOS per visit       
         Mean Average LOS per visit ±S.D. (days) 15.0± 13.6 11.7± 14.3 14.0± 13.9 16.2± 20.6 14.0± 19.2 15.5± 20.2 
         % with Average LOS per visit ≤7 days 49.8 61.2 53.4 37.4 44.3 39.5 
         % with Average LOS per visit >7 days 50.2 38.8 46.6 62.6 55.7 60.5 
      Number of Hospitalizations       
         % with 0-1 hospitalization 80.9 85.0 82.1 35.1 48.1 39.1 
         % with ≥2 hospitalizations 19.1 15.0 17.9 64.9 51.9 60.9 
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   ICU Admission       
      % with an ICU Admission 0.6 5.0 2.0 2.3 6.4 2.9 
 
Table 4.4 summarizes the hospital services consumption in each disease group (COPD and lung cancer) and the total study population 
stratified by comorbid conditions (0-1 and ≥2 conditions). Overall, decedents with multiple comorbid conditions had greater usage 
than those with one or zero comorbid condition. In the last one month of life, there was not a significant difference in hospital stays 
between different comorbidity categories. Interestingly, patients with multiple comorbid conditions (Percentage of two or more 
hospitalizations: 16.3%) were less likely to visit hospitals twice or more when compared with those having one or zero comorbid 
condition (Percentage of two or more hospitalizations: 24.0%).    
 
Table 4.4 Hospitalization in patients with COPD and Lung Cancer by disease group and length of time prior to death stratified by 
comorbid condition 
   1 Month   6 Months  
  Lung Cancer COPD Total Lung Cancer COPD Total 
0-1 condition       
   In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 13.9± 18.2 10.2± 14.9 12.8± 17.3 25.6± 25.3 22.6± 24.8 24.7± 25.2 
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         % with Total LOS ≤7 days 41.2 54.2 45.1 22.6 31.0 25.1 
         % with Total LOS >7 days 58.8 45.8 54.9 77.4 69.0 74.9 
      Average LOS per visit       
         Mean Average LOS per visit ±S.D. (days) 14.5± 16.9 11.2± 13.4 13.5± 16.0 11.9± 17.2 9.7± 12.2 11.2± 15.9 
         % with Average LOS per visit ≤7 days 52.7 62.3 55.6 49.0 53.6 50.4 
         % with Average LOS per visit >7 days 47.3 37.7 44.4 51.0 46.4 49.6 
      Number of Hospitalizations       
         % with 0-1 hospitalization 74.6 79.3 76.0 23.3 35.3 26.9 
         % with ≥2 hospitalizations 25.4 20.7 24.0 76.7 64.7 73.1 
   ICU Admission       
      % with an ICU Admission 1.0 3.3 1.7 1.5 3.9 2.2 
≥2 conditions       
   In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 13.3± 14.4 10.3± 12.9 12.2± 14.0 27.2± 25.6 24.8± 27.0 26.4± 26.1 
         % with Total LOS ≤7 days 41.3 53.4 45.5 19.2 27.5 22.0 
         % with Total LOS >7 days 58.7 46.6 54.5 80.8 72.5 78.0 
      Average LOS per visit       
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         Mean Average LOS per visit ±S.D. (days) 14.3± 12.5 11.8± 11.5 13.4± 12.2 16.1± 19.1 15.5± 21.2 15.9± 19.8 
         % with Average LOS per visit ≤7 days 48.6 57.9 51.8 35.0 38.2 36.1 
         % with Average LOS per visit >7 days 51.4 42.1 48.2 65.5 61.8 63.9 
      Number of Hospitalizations       
         % with 0-1 hospitalization 81.7 87.6 83.7 43.5 54.3 47.3 
         % with ≥2 hospitalizations 18.3 12.4 16.3 56.5 45.7 52.7 
   ICU Admission       
      % with an ICU Admission 1.0 4.9 2.4 1.9 6.1 3.4 
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Table 4.5 suggests that there are differences across age groups in the consumption of hospital services in both the last one month and 
six months of life. Usage of decedents aged 60 to 69 years was higher than that in any other age groups, while the oldest age group (≥ 
90 years) consumed the least amount of hospital care services. Regarding the difference between disease groups in each age category, 
usage differed much more on the older age groups than in the younger age groups.   
 
Table 4.5 Hospitalization in patients with COPD and Lung Cancer by disease group and length of time prior to death stratified by age 
   1 Month   6 Months  
  Lung Cancer COPD Total Lung Cancer COPD Total 
≤59 years             
   In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 13.2± 16.4 14.0± 26.1 13.2± 17.3 26.2± 24.4 29.7± 39.4 26.5± 25.8 
         % with Total LOS ≤7 days 43.6 51.0 44.2 21.6 30.6 22.3 
         % with Total LOS >7 days 56.4 49.0 55.8 78.4 69.4 77.7 
      Average LOS per visit       
         Mean Average LOS per visit ±S.D. (days) 13.6± 15.8 13.5± 26.8 13.6± 17.0 13.0± 15.6 14.4± 31.1 13.1± 17.2 
         % with Average LOS per visit ≤7 days 53.1 61.2 53.7 46.1 55.1 46.7 
         % with Average LOS per visit >7 days 46.9 38.8 46.3 53.9 44.9 53.3 
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      Number of Hospitalizations       
         % with 0-1 hospitalization 75.4 65.3 74.7 28.2 36.7 28.8 
         % with ≥2 hospitalizations 24.6 34.7 25.3 71.8 63.3 71.2 
   ICU Admission       
      % with an ICU Admission 0.5 2.0 0.6 1.0 8.2 1.5 
60-69 years       
   In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 14.1± 17.6 12.1± 20.4 13.7± 18.1 27.1± 26.2 29.4± 33.4 27.5± 27.5 
         % with Total LOS ≤7 days 39.6 51.3 41.5 19.9 25.7 20.8 
         % with Total LOS >7 days 60.4 48.7 58.5 80.1 74.3 79.2 
      Average LOS per visit       
         Mean Average LOS per visit ±S.D. (days) 14.7± 14.9 11.8± 13.5 14.2± 14.7 14.3± 19.2 14.3± 24.4 14.3± 20.1 
         % with Average LOS per visit ≤7 days 50.5 60.9 52.1 42.3 45.7 42.8 
         % with Average LOS per visit >7 days 49.5 39.1 47.9 57.7 54.3 57.2 
      Number of Hospitalizations       
         % with 0-1 hospitalization 77.4 77.0 77.3 31.9 35.7 32.5 
         % with ≥2 hospitalizations 22.6 23.0 22.7 68.1 64.3 67.5 
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   ICU Admission       
      % with an ICU Admission 0.9 7.8 2.0 1.7 9.1 2.9 
70-79 years       
   In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 13.9± 15.3 11.1± 11.8 13.0± 14.4 27.6± 26.5 25.3± 26.8 26.9± 26.6 
         % with Total LOS ≤7 days 38.7 50.3 42.2 18.2 26.9 20.8 
         % with Total LOS >7 days 61.3 49.7 57.8 81.8 73.1 79.2 
      Average LOS per visit       
         Mean Average LOS per visit ±S.D. (days) 14.6± 13.8 12.0± 10.0 13.8± 12.8 14.5± 19.0 14.1± 19.7 14.4± 19.2 
         % with Average LOS per visit ≤7 days 47.8 55.2 50.1 38.1 41.2 39.1 
         % with Average LOS per visit >7 days 52.2 44.8 49.9 61.9 58.8 60.9 
      Number of Hospitalizations       
         % with 0-1 hospitalization 76.7 84.7 79.2 32.7 45.9 36.7 
         % with ≥2 hospitalizations 23.3 15.3 20.8 67.3 54.1 63.3 
   ICU Admission       
      % with an ICU Admission 1.5 4.5 2.5 2.3 6.5 3.6 
80-89 years       
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   In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 12.5± 15.6 9.4± 11.7 11.0± 13.9 24.9± 23.9 22.4± 23.8 23.6± 23.9 
         % with Total LOS ≤7 days 45.0 55.3 50.1 23.8 30.1 27.0 
         % with Total LOS >7 days 55.0 44.7 49.9 76.2 69.9 73.0 
      Average LOS per visit       
         Mean Average LOS per visit ±S.D. (days) 14.3± 14.3 11.1± 10.9 12.7± 12.8 14.8± 18.4 12.8± 16.2 13.8± 17.3 
         % with Average LOS per visit ≤7 days 51.9 60.8 56.4 40.5 44.3 42.4 
         % with Average LOS per visit >7 days 48.1 39.2 43.6 59.5 55.7 57.6 
      Number of Hospitalizations       
         % with 0-1 hospitalization 84.2 86.5 85.3 44.7 50.4 47.6 
         % with ≥2 hospitalizations 15.8 13.5 14.7 55.3 49.6 52.4 
   ICU Admission       
      % with an ICU Admission 0.7 3.7 2.2 1.3 4.1 2.7 
≥90 years       
   In-patient Hospitalization       
      Total LOS in Hospital       
         Mean Total LOS ±S.D. (days) 10.6± 10.8 7.9± 20.7 8.8± 17.8 22.8± 22.7 18.8± 19.7 20.3± 20.8 
  
 
 
 
6
3 
         % with Total LOS ≤7 days 52.2 70.4 63.8 28.3 33.3 31.5 
         % with Total LOS >7 days 47.8 29.6 36.2 71.7 66.7 68.5 
      Average LOS per visit       
         Mean Average LOS per visit ±S.D. (days) 13.2± 10.7 10.7± 24.5 11.7± 20.2 16.0± 17.8 11.5± 13.0 13.1± 15.0 
         % with Average LOS per visit ≤7 days 56.5 74.1 67.7 39.1 48.1 44.9 
         % with Average LOS per visit >7 days 43.5 25.9 32.3 60.9 51.9 55.1 
      Number of Hospitalizations       
         % with 0-1 hospitalization 91.3 87.7 89.0 54.3 56.8 55.9 
         % with ≥2 hospitalizations 8.7 12.3 11.0 45.7 43.2 44.1 
   ICU Admission       
      % with an ICU Admission 0 0 0 0 0 0 
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4.2 Research Question 2 
Is there an association between the following independent variables and hospitalization 
among the target population and do they modify the effect of diagnostic group? 
 (a) age 
 (b) comorbidity 
 (c) sex 
 
The main effect variables included in this analysis are disease status, age, sex, and comorbid 
condition. The univariate associations between hospital utilization, including total LOS in 
hospitals, average LOS per hospitalization and number of hospitalizations, and the covariates are 
presented in Tables 4.6 and 4.7. 
 
According to Table 4.6, in the last six months of life, among nine factors, eight of them were 
significantly associated with the Total LOS > 7 days independently. The only exception was for 
institutional supportive care services. However, it was still included in all multivariate analyses 
as suggested by literature. 
 
It was observed that having COPD as the UCOD decreased the likelihood of having a total LOS 
greater than 7 days (OR= 0.64, 95%CI= 0.57-0.72). Decedents aged 80 years or above were less 
likely to stay longer in hospital than those aged 59 years or below. Male subjects were observed 
to have reduced odds of staying in hospital longer than 7 days. Living in rural areas was 1.25 
times more likely to have longer hospital stay as compared to residents in urban areas. The odds 
were increased by 1.19 times among decedents with multiple comorbid conditions. The odds 
however were observed to be reduced by 0.65 times among subjects who died outside of the 
hospital when compared with those died in hospital. With regards to marital status, being 
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widowed decreased the odds of staying in hospital greater than 7 days. Number of transfers 
between institutional supportive care facilities doubled the likelihood of staying longer in 
hospital as compared to without transfers. 
 
In the last month of life, seven out of nine independent variables were significantly associated 
with the Total LOS > 7days. Sex, comorbid condition, and marital status were not significantly 
associated with total LOS. However, they were included in all multivariate analyses since they 
were main effect factors of interest in this study and could be confounders in the analysis. 
Subjects who were died of COPD had a reduced probability of longer hospital stay (OR=0.61, 
95%CI= 0.55-0.67). It was observed that rural residents were more likely to have longer hospital 
duration as compared to urban residents. Subjects who were at an age of 80 years and above, 
died out of hospital, had institutional supportive care services, and had transfers between 
institutional supportive care facilities had reduced likelihood of prolonged hospital stay. 
 
In the last six months of life, all factors were significantly associated with the Average LOS per 
hospitalization > 7days at the univariate level. The odds were reduced by 0.88 times among 
decedents with COPD when compared with decedents from lung cancer (OR= 0.88, 95%CI= 
0.80-0.98). Male subjects were observed to have reduced odds of greater average LOS per visit. 
Compared with those at an age of 59 years or below, individuals at an age of 70-79 years were 
more likely to spend more than seven days in hospitals. In addition, subjects with multiple 
comorbid illnesses, never married or separated/ divorced, had institutional supportive care 
services, and had transfers between supportive care institutions, had increased odds of longer 
LOS per hospitalization.  
 
In the last month of life, sex was observed to have no statistically significant relationship with 
the Average LOS per visit > 7days at the univariate level. However, this factor was still included 
in all the multivariate analyses as it was of one of the primary interest. Decedents with COPD 
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were observed to have reduced odds of longer average hospital stay (OR= 0.69, 95%CI= 0.62-
0.76). Subjects with multiple comorbid conditions and never married were found to have 
prolonged hospital stay.  
 
Regarding the number of hospitalizations, as indicated by Table 4.7, in the six months before 
death, sex was found to have no statistically significant relationship with ≥ 2 hospitalizations at 
the univariate level. However, sex was still included in all the multivariate analyses as it was one 
of the main effect factors of interest. COPD as UCOD was found to reduce the likelihood of ≥ 2 
hospitalizations. Other factors that reduced hospital attendance included advancing age, multiple 
comorbid conditions, out-of-hospital death, unmarried status, and having institutional supportive 
care services. Rural residence was associated with an increased likelihood of frequent hospital 
attendance.  
 
In the last month of life, all independent variables were significantly associated with ≥ 2 
hospitalizations individually. Subjects who died of COPD had less probability of having frequent 
hospital attendance as compared with their lung cancer counterparts (OR= 0.68, 95%CI= 0.59- 
0.77). Male sex and rural residence increased the odds of two or more hospital admissions. 
However, aging, multiple comorbid conditions, out-of-hospital death, unmarried status, receiving 
long-term supportive care, and transfer between supportive care facilities were found to reduce 
the likelihood of frequent hospitalizations. 
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Table 4.6 Univariate Analysis examining associations with LOS in Hospital 
 Total LOS > 7 days in 
Hospital in the 6 months prior 
to death 
Total LOS > 7 days in 
Hospital in the 1 month prior 
to death 
Average LOS per visit >7 
days in the 6 months prior to 
death 
Average LOS per visit >7 
days in the 1 month prior to 
death 
 Unadjusted OR 
(95%CI) 
P-value Unadjusted OR 
(95%CI) 
P-value Unadjusted OR 
(95%CI) 
P-value Unadjusted OR 
(95%CI) 
P-value 
Disease status         
  Lung Cancer  1.00  1.00  1.00  1.00  
  COPD 0.64 (0.57, 0.72) <0.0001 0.61 (0.55, 0.67) <0.0001 0.88 (0.80, 0.98) 0.02 0.69 (0.62, 0.76) <0.0001 
Age          
  ≤59 years       1.00  1.00  1.00  1.00  
  60-69 years 1.09 (0.87, 1.37) 0.44 1.12 (0.93, 1.34) 0.25 1.17 (0.97, 1.41) 0.09 1.07 (0.89, 1.28) 0.50 
  70-79 years 1.09 (0.89, 1.34) 0.41 1.08 (0.91, 1.29) 0.37 1.37 (1.15, 1.63) <0.0001 1.16 (0.98, 1.38) 0.10 
  80-89 years 0.78 (0.63, 0.95) 0.02 0.79 (0.66, 0.94) 0.007 1.19 (1.00, 1.42) 0.05 0.90 (0.76, 1.07) 0.22 
  ≥90 years 0.62 (0.41, 0.95) 0.03 0.45 (0.30, 0.67) <0.0001 1.08 (0.74, 1.58) 0.70 0.55 (0.37, 0.83) 0.004 
Sex         
  Female  1.00  1.00  1.00  1.00  
  Male 0.89 (0.79, 0.99) 0.04 1.00 (0.91, 1.10) 0.99 0.86 (0.78, 0.94) 0.002 1.01 (0.91, 1.11) 0.92 
Residence          
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  ≥300,000 1.00  1.00  1.00  1.00  
  (10,000- 299,999) 0.95 (0.81, 1.11) 0.52 0.98 (0.85, 1.12) 0.73 1.07 (0.94, 1.23) 0.31 1.09 (0.95, 1.25) 0.20 
  <10,000 1.25 (1.11, 1.41) <0.0001 1.15 (1.03, 1.27) 0.01 1.09 (0.98, 1.21) 0.11 1.11 (1.00, 1.23) 0.05 
Comorbid Condition         
  0-1  1.00  1.00  1.00  1.00  
  ≥2 1.19 (1.06, 1.33) 0.003 0.99 (0.90, 1.09) 0.78 1.80 (1.63, 1.98) <0.0001 1.17 (1.06, 1.28) 0.002 
Location of Death         
  Hospital  1.00  1.00  1.00  1.00  
  Outside Hospital 0.65 (0.57, 0.73) <0.0001 0.24 (0.21, 0.27) <0.0001 0.81 (0.73, 0.91) <0.0001 0.29 (0.26, 0.33) <0.0001 
Marital Status         
  Married/ Common Law  1.00  1.00  1.00  1.00  
  Never Married 1.16 (0.94, 1.44) 0.16 1.13 (0.95, 1.34) 0.18 1.35 (1.14, 1.62) 0.001 1.22 (1.03, 1.45) 0.02 
  Separated/ Divorced 1.00 (0.87, 1.14) 0.97 0.96 (0.85, 1.07) 0.44 1.17 (1.04, 1.32) 0.009 1.06 (0.95, 1.20) 0.30 
  Widowed 0.85 (0.73, 0.99) 0.04 0.90 (0.79, 1.02) 0.10 1.11 (0.97, 1.27) 0.12 1.00 (0.88, 1.14) 0.97 
Institutional supportive care services        
  No  1.00  1.00  1.00  1.00  
  Yes 1.04 (0.92, 1.19) 0.50 0.52 (0.46, 0.57) <0.0001 1.44 (1.29, 1.61) <0.0001 0.61 (0.55, 0.68) <0.0001 
Transfers between institutional supportive care facilities       
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  No  1.00  1.00  1.00  1.00  
  Yes  2.00 (1.42, 2.80) <0.0001 0.28 (0.21, 0.36) <0.0001 2.77 (2.09, 3.67) <0.0001 0.31 (0.24, 0.41) <0.0001 
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Table 4.7 Univariate Analysis examining associations with Number of Hospitalizations 
 N ≥ 2 hospitalizations in the 6 
months prior to death  
≥ 2 hospitalizations in the 1 
month prior to death 
  Unadjusted OR 
(95%CI) 
P-value Unadjusted OR 
(95%CI) 
P-value 
Disease status      
  Lung Cancer  4782 1.00  1.00  
  COPD 2332 0.60 (0.54, 0.67) <0.0001 0.68 (0.59, 0.77) <0.0001 
Age       
  ≤59 years       659 1.00  1.00  
  60-69 years 1427 0.84 (0.69, 1.03) 0.09 0.87 (0.70, 1.07) 0.19 
  70-79 years 2471 0.70 (0.58, 0.84) <0.0001 0.78 (0.64, 0.95) 0.01 
  80-89 years 2430 0.45 (0.37, 0.54) <0.0001 0.51 (0.41, 0.62) <0.0001 
  ≥90 years 127 0.32 (0.22, 0.47) <0.0001 0.37 (0.20, 0.65) 0.001 
Sex      
  Female  2822 1.00  1.00  
  Male 4292 0.99 (0.90, 1.10) 0.88 1.17 (1.04, 1.32) 0.01 
Residence       
  ≥300,000 2498 1.00  1.00  
  (10,000- 299,999) 1270 0.94 (0.82, 1.07) 0.33 1.05 (0.88, 1.26) 0.56 
  <10,000 3346 1.22 (1.10, 1.36) <0.0001 1.42 (1.24, 1.62) <0.0001 
Comorbid Condition      
  0-1  2823 1.00  1.00  
  ≥2 4291 0.41 (0.37, 0.46) <0.0001 0.62 (0.55, 0.69) <0.0001 
Location of Death      
  Hospital  5226 1.00  1.00  
  Outside Hospital 1882 0.55 (0.50, 0.62) <0.0001 0.32 (0.27, 0.38) <0.0001 
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Marital Status      
  Married/ Common Law  3668 1.00  1.00  
  Never Married 1617 0.63 (0.53, 0.75) <0.0001 0.85 (0.68, 1.05) 0.13 
  Separated/ Divorced 1663 0.80 (0.71, 0.90) <0.0001 0.79 (0.68, 0.92) 0.002 
  Widowed 1166 0.69 (0.61, 0.79) <0.0001 0.74 (0.63, 0.89) 0.001 
Institutional supportive care services     
  No  5285 1.00  1.00  
  Yes 1829 0.72 (0.65, 0.80) <0.0001 0.50 (0.42, 0.58) <0.0001 
Transfers between institutional supportive care facilities    
  No  6817 1.00  1.00  
  Yes  297 0.83 (0.66, 1.05) 0.13 0.37 (0.25, 0.56) <0.0001 
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As shown in Table 4.8, in the last six months of life, most factors were significantly associated 
with the Total LOS > 7 days in hospitals. Exceptions were age and marital status. Decedents with 
COPD were less likely to spend more than seven days in hospitals compared to their lung cancer 
counterparts (OR=0.64, 95%CI= 0.56-0.72). Male decedents had a reduced likelihood of 
prolonged hospital stay as compared with female decedents. The odds of longer hospital duration 
for rural residents were 1.32 times greater than that for urban residents. Subjects with multiple 
comorbid conditions were more likely to stay hospital longer than those with one or zero 
comorbid condition. Subjects who died out of hospital had a reduced probability by 0.55 times 
that of those who died in hospital for a longer hospital stay. The probability of having Total LOS 
>7 increased by 1.31 times among those receiving institutional supportive care services as 
compared to subjects without it. Subjects with transfers between supportive care institutions 
were 2.57 times more likely to have a longer stay in hospitals than those without transfers.  
 
In the last month of life, sex, comorbid conditions and institutional supportive care services were 
not statistically associated with the Total LOS > 7 days in hospitals. Subjects who died of COPD 
had a reduced likelihood of a longer hospital stay (OR=0.61, 95%CI= 0.52-0.68). In addition, 
out-of-hospital death and transfers between supportive care institutions also decreased the 
probability of longer hospital stay. Subjects aged 60-69 and 70-79 years were 1.22 times and 
1.13 times more likely to have longer hospital stay as compared to subjects aged 59 years or 
below. Residing in rural areas also increased the probability by 1.20 times as compared to those 
in urban areas. Those never married also increase the odds of having prolonged hospital stay by 
1.29 times as compared to those married or common law. 
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Table 4.8 Multivariate Analysis examining associations with Total LOS in Hospital 
 Total LOS > 7 days in Hospital 
in the 6 months prior to death 
Total LOS > 7 days in Hospital 
in the 1 month prior to death 
 Adjusted OR 
(95%CI) 
P-value Adjusted OR 
(95%CI) 
P-value 
Disease status     
  Lung Cancer  1.00  1.00  
  COPD 0.64 (0.56, 0.72) <0.0001 0.61 (0.52, 0.68) <0.0001 
Age      
  ≤59 years       1.00  1.00  
  60-69 years 1.15 (0.92, 1.44) 0.23 1.22 (1.00, 1.48) 0.05 
  70-79 years 1.20 (0.97, 1.49) 0.10 1.31 (1.09, 1.57) 0.005 
  80-89 years 0.92 (0.74, 1.14) 0.44 1.16 (0.96, 1.41) 0.13 
  ≥90 years 0.74 (0.48, 1.14) 0.17 0.73 (0.48, 1.12) 0.15 
Sex     
  Female  1.00  1.00  
  Male 0.88 (0.78, 0.99) 0.04 0.99 (0.89, 1.10) 0.78 
Residence      
  ≥300,000 1.00  1.00  
  (10,000- 299,999) 1.01 (0.86, 1.18) 0.96 0.99 (0.86, 1.15) 0.94 
  <10,000 1.32 (1.16, 1.49) <0.0001 1.20 (1.07, 1.34) 0.002 
Comorbid Condition     
  0-1  1.00  1.00  
  ≥2 1.23 (1.09, 1.38) <0.0001 1.04 (0.94, 1.15) 0.44 
Location of Death     
  Hospital  1.00  1.00  
  Outside Hospital 0.55 (0.48, 0.62) <0.0001 0.23 (0.22, 0.28) <0.0001 
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Marital Status     
  Married/ Common Law  1.00  1.00  
  Never Married 1.18 (0.95, 1.47) 0.13 1.29 (1.07, 1.55) 0.008 
  Separated/ Divorced 1.03 (0.89, 1.20) 0.67 1.11 (0.98, 1.26) 0.12 
  Widowed 0.90 (0.77, 1.06) 0.21 1.07 (0.92, 1.24) 0.39 
Institutional supportive care services    
  No  1.00  1.00  
  Yes 1.31 (1.12, 1.52) 0.001 1.04 (0.91, 1.19) 0.57 
Transfers between institutional supportive care facilities   
  No  1.00  1.00  
  Yes  2.57 (1.83, 3.62) <0.0001 0.49 (0.37, 0.66) <0.0001 
Adjusted for all the variables in the table. 
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As shown in Table 4.9, in the six months prior to death, all factors were significantly associated 
with the Average LOS per visit > 7 days in hospitals. Subjects who died of COPD (OR=0.78, 
95%CI= 0.70-0.87), being male, and died out of hospital had a reduced probability of a longer 
hospital stay. The odds of prolonged stay increased by 1.22 times and 1.40 times among subjects 
aged 60-69 and 70-79 respectively as compared to those aged 59 years and below. In addition, 
residing in rural areas, having multiple comorbid illnesses, having institutional supportive care 
services and having transfers were also associated with an increased risk of prolonged 
hospitalization.   
 
In the last month of life, the risk of having an average LOS per visit > 7 days in hospital was 
found to be reduced among those who died of COPD (OR= 0.67, 95%CI= 0.60-0.75). Other 
factors that reduced the likelihood of prolonged hospital stay per visit included out-of-hospital 
death and having transfers between supportive care institutions. However, subjects who were at 
an age of 70-79 years, residing in rural areas, with two or more comorbid conditions, having 
institutional supportive care services were at an increased risk of longer hospital stay. The odds 
increased by 1.36 times and 1.20 times among those never married and separated / divorced 
respectively as compared to those married or in common law. Sex was observed to have no 
significant association with the Average LOS per visit > 7 days.  
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Table 4.9 Multivariate Analysis examining associations with Average LOS per Hospitalization 
 Average LOS per visit >7 days 
in the 6 months prior to death 
Average LOS per visit >7 days 
in the 1 month prior to death 
 Adjusted OR 
(95%CI) 
P-value Adjusted OR 
(95%CI) 
P-value 
Disease status     
  Lung Cancer  1.00  1.00  
  COPD 0.78 (0.70, 0.87) <0.0001 0.67 (0.60, 0.75) <0.0001 
Age      
  ≤59 years       1.00  1.00  
  60-69 years 1.22 (1.01, 1.48) 0.04 1.14 (0.94, 1.38) 0.18 
  70-79 years 1.40 (1.17, 1.67) <0.0001 1.33 (1.11, 1.60) 0.002 
  80-89 years 1.17 (0.97, 1.42) 0.10 1.20 (0.99, 1.45) 0.07 
  ≥90 years 0.96 (0.64, 1.43) 0.83 0.79 (0.52, 1.22) 0.29 
Sex     
  Female  1.00  1.00  
  Male 0.86 (0.77, 0.95) 0.003 1.01 (0.91, 1.12) 0.83 
Residence      
  ≥300,000 1.00  1.00  
  (10,000- 299,999) 1.15 (1.00, 1.32) 0.06 1.13 (0.98, 1.30) 0.09 
  <10,000 1.17 (1.05, 1.31) 0.004 1.16 (1.04, 1.30) 0.007 
Comorbid Condition     
  0-1  1.00  1.00  
  ≥2  1.81 (1.64, 2.00) <0.0001 1.23 (1.11, 1.36)  <0.0001 
Location of Death     
  Hospital  1.00  1.00  
  Outside Hospital 0.62 (0.55, 0.70) <0.0001 0.30 (0.26, 0.34) <0.0001 
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Marital Status     
  Married/ Common Law  1.00  1.00  
  Never Married 1.34 (1.12, 1.61) 0.001 1.36 (1.13, 1.63) 0.001 
  Separated/ Divorced 1.11 (0.97, 1.25) 0.12 1.20 (1.06, 1.36) 0.005 
  Widowed 1.02 (0.89, 1.18) 0.75 1.14 (0.98, 1.32) 0.09 
Institutional supportive care services    
  No  1.00  1.00  
  Yes 1.52 (1.33, 1.73) <0.0001 1.10 (1.06, 1.26) <0.0001 
Transfers between institutional supportive care facilities   
  No  1.00  1.00  
  Yes  2.55 (1.91, 3.40) <0.0001 0.47 (0.35, 0.63) <0.0001 
Adjusted for all the variables in the table. 
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As seen in Table 4.10, in the last six months of life, COPD as UCOD reduced the risk for having 
≥ 2 hospitalizations (OR= 0.71, 95%CI= 0.64-0.80). Other protective factors were aging, 
multiple comorbid conditions, outside-hospital death and never married and widowed. The risk 
however increased among rural residents and with transfers between supportive care institutions 
by 1.16 times and 1.41 times respectively.   
 
In the last month of life, decedents with COPD had reduced likelihood of having ≥ 2 
hospitalizations (OR= 0.81, 95%CI= 0.70- 0.93). The risk also decreased with aging, multiple 
comorbid conditions, out-of-hospital death, and having institutional supportive care services. 
Being male and living in rural areas were risk factors of frequent hospital admissions.  
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Table 4.10 Multivariate Analysis examining associations with Number of Hospitalizations 
 ≥ 2 hospitalizations in the 6 
months prior to death  
≥ 2 hospitalizations in the 1 
month prior to death 
 Adjusted OR 
(95%CI) 
P-value Adjusted OR 
(95%CI) 
P-value 
Disease status     
  Lung Cancer  1.00  1.00  
  COPD 0.71 (0.64, 0.80) <0.0001 0.81 (0.70, 0.93) 0.003 
Age      
  ≤59 years       1.00  1.00  
  60-69 years 0.83 (0.67, 1.02) 0.08 0.86 (0.69, 1.08) 0.20 
  70-79 years 0.75 (0.62, 0.91) 0.004 0.83 (0.67, 1.02) 0.08 
  80-89 years 0.53 (0.43, 0.64) <0.0001 0.62 (0.49, 0.78) <0.0001 
  ≥90 years 0.44 (0.29, 0.66) <0.0001 0.52 (0.28, 0.95) 0.03 
Sex     
  Female  1.00  1.00  
  Male 0.99 (0.90, 1.11) 0.98 1.18 (1.04, 1.34) 0.01 
Residence      
  ≥300,000 1.00  1.00  
  (10,000- 299,999) 0.93 (0.81, 1.07) 0.33 1.04 (0.87, 1.25) 0.66 
  <10,000 1.16 (1.04, 1.30) 0.01 1.41 (1.23, 1.62) <0.0001 
Comorbid Condition     
  0-1  1.00  1.00  
  ≥2 0.41 (0.37, 0.46) <0.0001 0.65 (0.57, 0.73) <0.0001 
Location of Death     
  Hospital  1.00  1.00  
  Outside Hospital 0.53 (0.47, 0.60) <0.0001 0.36 (0.30, 0.43) <0.0001 
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Marital Status     
  Married/ Common Law  1.00  1.00  
  Never Married 0.63 (0.53, 0.76) <0.0001 0.88 (0.70, 1.10) 0.27 
  Separated/ Divorced 0.91 (0.80, 1.03) 0.14 0.97 (0.82, 1.13) 0.66 
  Widowed 0.86 (0.74, 1.00) 0.04 0.99 (0.82, 1.19) 0.90 
Institutional supportive care services    
  No  1.00  1.00  
  Yes 1.10 (0.97, 1.26) 0.15 0.81 (0.68, 0.97) 0.02 
Transfers between institutional supportive care facilities   
  No  1.00  1.00  
  Yes  1.41 (1.01, 1.81) 0.008 0.82 (0.53, 1.26) 0.36 
Adjusted for all the variables in the table. 
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Disease status and sex, disease status and age, and disease status and comorbid condition were 
also tested for interaction in each model (Table 4.11, 4.12, 4.13). The overall Likelihood ratio 
test was used to confirm the inclusion of the interaction term in the model.  
 
In the last six months of life, sex was an effect modifier in the association between disease status 
and total LOS in hospitals (P=0.045 with log-likelihood difference= 4.023 for 1 d.f.). The 
interaction between sex and disease status contributed significantly to the prediction of the 
probability of having total LOS greater than 7 days in hospitals in the last month of life (P=0.025 
with log-likelihood difference= 5.032 for 1 d.f.). Stratified analysis showed that while those with 
COPD were less likely to have a long hospital stay than those with lung cancer, the protective 
effect was weaker among males than females. 
 
In the six months prior to death, sex was an effect modifier in the association between disease 
status and average LOS per visit > 7 days in hospitals (P=0.001 with log-likelihood difference= 
10.098 for 1 d.f.). However, in the last month of life, sex did not modify the relationship between 
disease status and average LOS in hospitals (P=0.072 with log-likelihood difference=3.246 for 1 
d.f.). Stratified analysis showed that while decedents with COPD were less likely to have a 
longer hospital than decedents with lung cancer, the protective effect was weaker among males 
than females.  
 
Age was an effect modifier in the relationship between disease status and number of 
hospitalizations in the six months prior to death (P=0.031 with log-likelihood difference=10.614 
for 1 d.f.). The interaction between age and disease status contributed significantly to the 
prediction of the probability of having two or more hospital attendance in the last month of life 
(P=0.003 with log-likelihood difference=14.482 for 1 d.f.). Stratified analysis indicated that 
while those with COPD were less likely to have frequent hospital admissions than those with 
lung cancer, the protective effect was stronger among those aged 70-79 years than the others.  
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Table 4.11 Association between disease status and each outcome stratified by sex, comorbid 
condition or age with total LOS in hospital 
 Total LOS >7 days in Hospital in 
the 6 months prior to death 
Total LOS >7 days in Hospital in the 1 
month prior to death 
 Adjusted OR (95% CI) Adjusted OR (95% CI) 
Sex   
    Male 
 Lung cancer 
 COPD 
 
1.00 
0.67 (0.57, 0.79)
 *
 
 
1.00 
0.64 (0.55, 0.74)
 *
 
    Female   
              Lung cancer 1.00 1.00 
              COPD 0.57 (0.46, 0.70) 0.54 (0.45, 0.65) 
Comorbid Condition  
    0-1 condition   
              Lung cancer 1.00 1.00 
              COPD 0.67 (0.55, 0.82) 0.61 (0.51, 0.73) 
    ≥2 conditions   
              Lung cancer 1.00 1.00 
              COPD 0.60 (0.51, 0.71) 0.60 (0.52, 0.69) 
Age   
    ≤59 years   
              Lung cancer 1.00 1.00 
              COPD 0.66 (0.34, 1.29) 0.65 (0.35, 1.19) 
    60-69 years   
              Lung cancer 1.00 1.00 
              COPD 0.66 (0.47, 0.92) 0.53 (0.39, 0.72) 
    70-79 years   
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              Lung cancer 1.00 1.00 
              COPD 0.58 (0.47, 0.71) 0.56 (0.47, 0.68) 
    80-89 years   
              Lung cancer 1.00 1.00 
              COPD 0.69 (0.57, 0.83) 0.68 (0.58, 0.81) 
    ≥90 years   
              Lung cancer 1.00 1.00 
              COPD 0.65 (0.26, 1.59) 0.53 (0.22, 1.28) 
*
P<0.05 based on Wald test for interaction 
+
P<0.10 based on Wald test for interaction 
Adjusted for residence, marital status, location of death, institutional supportive care services and transfers between 
institutional supportive care facilities. 
Overall Likelihood Ratio test with Total LOS in Hospital 6 months prior to death adding interaction term disease 
status*sex: P=0.045 (difference= 4.023 with df=1) 
Overall Likelihood Ratio test with Total LOS in Hospital 1 month prior to death deaths adding interaction term 
disease status*sex: P=0.025 (difference= 5.032 with df=1) 
Overall Likelihood Ratio test with Total LOS in Hospital 6 months prior to death adding interaction term disease 
status*age: P=0.562 (difference= 0.336 with df=1) 
Overall Likelihood Ratio test with Total LOS in Hospital 1 month prior to death adding interaction term disease 
status*age: P=0.93 (difference= 0.080 with df=1) 
Overall Likelihood Ratio test with Total LOS in Hospital 6 months prior to death adding interaction term disease 
status*comorbidity: P=0.733 (difference= 2.016 with df=4) 
Overall Likelihood Ratio test with Total LOS in Hospital 1 month prior to death adding interaction term disease 
status*comorbidity: P=0.596 (difference= 2.776 with df=4) 
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Table 4.12 Association between disease status and each outcome stratified by sex, comorbid 
condition or age with average LOS per hospitalization 
 Average LOS >7 days in Hospital 
in the 6 months prior to death 
Average LOS >7 days in Hospital in 
the 1 month prior to death 
 Adjusted OR (95% CI) Adjusted OR (95% CI) 
Sex   
    Male 
 Lung cancer 
 COPD 
 
1.00 
0.88 (0.77, 1.02)
 *
 
 
1.00 
0.70 (0.61, 0.81) 
+
 
    Female   
              Lung cancer 1.00 1.00 
              COPD 0.63 (0.53, 0.75) 0.61 (0.51, 0.73) 
Comorbid Condition  
    0-1condition   
              Lung cancer 1.00 1.00 
              COPD 0.78 (0.66, 0.93) 0.69 (0.58, 0.82) 
    ≥2 conditions   
              Lung cancer 1.00 1.00 
              COPD 0.77 (0.67, 0.89) 0.65 (0.57, 0.75) 
Age   
    ≤59 years   
              Lung cancer 1.00 1.00 
              COPD 0.68 (0.37, 1.24) 0.61 (0.33, 1.13) 
    60-69 years   
              Lung cancer 1.00 1.00 
              COPD 0.80 (0.60, 1.08) 0.58 (0.43, 0.78) 
    70-79 years   
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              Lung cancer 1.00 1.00 
              COPD 0.82 (0.68, 0.98) 0.69 (0.57, 0.82) 
    80-89 years   
              Lung cancer 1.00 1.00 
              COPD 0.78 (0.66, 0.92) 0.71 (0.60, 0.84) 
    ≥90 years   
              Lung cancer 1.00 1.00 
              COPD 0.62 (0.26, 1.47) 0.57 (0.24, 1.38) 
*
P<0.05 based on Wald test for interaction 
+
P<0.10 based on Wald test for interaction 
Adjusted for residence, marital status, location of death, institutional supportive care services and transfers between 
institutional supportive care facilities. 
Overall Likelihood Ratio test with Average LOS per Hospitalization 6 months prior to death adding interaction term 
disease status*sex: P=0.001 (difference= 10.098 with df=1) 
Overall Likelihood Ratio test with Average LOS per Hospitalization 1 month prior to death adding interaction term 
disease status*sex: P=0.072 (difference= 3.246 with df=1) 
Overall Likelihood Ratio test with Average LOS per Hospitalization 6 months prior to death adding interaction term 
disease status*comorbid condition: P=0.968 (difference= 0.002 with df=1) 
Overall Likelihood Ratio test with Average LOS per Hospitalization 1 month prior to death adding interaction term 
disease status*comorbid condition: P=0.946 (difference= 0.005 with df=1) 
Overall Likelihood Ratio test with Average LOS per Hospitalization 6 months prior to death adding interaction term 
disease status*age: P=0.860 (difference= 1.309 with df=4) 
Overall Likelihood Ratio test with Average LOS per Hospitalization 1 month prior to death adding interaction term 
disease status*age: P=0.758 (difference= 1.882 with df=4) 
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Table 4.13 Association between disease status and each outcome stratified by sex, comorbid 
condition or age with Number of Hospitalizations  
 >2 Hospitalizations in the 6 
months prior to death 
>2 Hospitalizations in the 1 month 
prior to death 
 Adjusted OR (95% CI) Adjusted OR (95% CI) 
Sex   
    Male 
 Lung cancer 
 COPD 
 
1.00 
0.71 (0.62, 0.82) 
 
1.00 
0.75 (0.63, 0.90) 
    Female   
              Lung cancer 1.00 1.00 
              COPD 0.71 (0.59, 0.85) 0.92 (0.72, 1.16) 
Comorbid Condition  
    0-1condition   
              Lung cancer 1.00 1.00 
              COPD 0.64 (0.53, 0.78) 0.92 (0.74, 1.13) 
    ≥2 conditions   
              Lung cancer 1.00 1.00 
              COPD 0.75 (0.66, 0.86) 0.72 (0.59, 0.87) 
Age   
    ≤59 years   
              Lung cancer 1.00 1.00 
              COPD 0.74 (0.39, 1.42) 1.69 (0.88, 3.25) 
    60-69 years   
              Lung cancer 1.00 1.00 
              COPD 0.83 (0.61, 1.12) 1.03 (0.73, 1.45) 
    70-79 years   
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              Lung cancer 1.00 1.00 
              COPD 0.57 (0.48, 0.69)
 *
 0.59 (0.47, 0.74)
 * 
 
    80-89 years   
              Lung cancer 1.00 1.00 
              COPD 0.81 (0.68, 0.96)
 *
 0.91 (0.72, 1.15)
 +
 
    ≥90 years   
              Lung cancer 1.00 1.00 
              COPD 0.85 (0.38, 1.92) 1.36 (0.34, 5.43) 
*P<0.05 based on Wald test for interaction 
+P<0.10 based on Wald test for interaction 
Adjusted for residence, marital status, location of death, institutional supportive care services and transfers between 
institutional supportive care facilities. 
Overall Likelihood Ratio test with Number of Hospitalizations 6 months prior to death adding interaction term 
disease status*sex: P=0.701 (difference= 0.147 with df=1) 
Overall Likelihood Ratio test with Number of Hospitalizations 1 month prior to death adding interaction term 
disease status*sex: P=0.274 (difference= 1.196 with df=1) 
Overall Likelihood Ratio test with Number of Hospitalizations 6 months prior to death adding interaction term 
disease status*comorbid condition: P=0.204 (difference= 1.613 with df=1) 
Overall Likelihood Ratio test with Number of Hospitalizations 1 month prior to death adding interaction term 
disease status*comorbid condition: P=0.153 (difference= 2.039 with df=1) 
Overall Likelihood Ratio test with Number of Hospitalizations 6 months prior to death adding interaction term 
disease status*age: P=0.031 (difference= 10.614 with df=4) 
Overall Likelihood Ratio test with Number of Hospitalizations 1 month prior to death adding interaction term 
disease status*age: P=0.003 (difference= 14.482 with df=4) 
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4.3 Research Question 3 
Does the pattern of hospitalization change over a 10 year period and are the associations 
between hospitalization and diagnostic group, age, sex, and comorbidity consistent over the 
10 year period? 
Table 4.14 describes the annual proportion of decedents in each disease group with greater 
hospital usage (Total LOS > 7days, Average LOS > 7days per hospitalization, ≥2 
hospitalizations). In the last month of life, fewer decedents had larger consumption of hospital 
services (Total LOS > 7days) in 2002 (OR=0.71) and in 2005 (OR=0.71). In the last six months 
of life, there was no significant change over the study period witnessed in the proportion of 
decedents with greater hospital service use. 
 
Over the ten-year study period, there was no significant change in the proportion of subjects with 
greater hospital use (Average LOS per hospitalization > 7 days) in either one month or six 
months prior to death.  
 
Regarding the frequency of hospital admissions, fewer subjects had more than two 
hospitalizations in 2001 (OR=0.54) in the last month of life. In the last six months of life, the 
proportion of decedents with more than 2 admissions in 2002, 2003 and 2005 were 
approximately 70% of that in 1997 (OR2002= 0.71, OR2003= 0.72, OR2005= 0.70).
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Table 4.14 Proportion with Hospitalization category by disease group and length of time prior to death between 1997 and 2006 
  1 month   6 months  
 Lung  Cancer  COPD OR (95% CI) Lung  Cancer  COPD OR (95% CI) 
 N(%) N(%)  N(%) N(%)  
Total  LOS >7 days     
1997 256 (9.1) 100 (10.9) 1.00 340 (9.0) 170 (10.2) 1.00 
1998 288 (10.3) 118 (10.9) 0.89 (0.66, 1.21) 373 (9.8) 169 (10.2) 0.91 (0.70, 1.17) 
1999 325 (11.6) 121 (11.2) 0.81 (0.60, 1.09) 437 (11.5) 188 (11.3) 0.86 (0.67, 1.11) 
2000 271 (9.6) 110 (10.2) 0.88 (0.65, 1.20) 366 (9.6) 168 (10.1) 0.92 (0.71, 1.19) 
2001 282 (10.0) 111 (10.3) 0.85 (0.63, 1.16) 378 (10.0) 166 (10.0) 0.88 (0.68, 1.14) 
2002 286 (10.2) 94 (8.7) 0.71 (0.52, 0.98)
†
 385 (10.1) 148 (8.9) 0.77 (0.59, 1.00)
*
 
2003 284 (10.1) 104 (9.6) 0.79 (0.58, 1.09) 390 (10.3) 161 (9.7) 0.83 (0.64, 1.07) 
2004 269 (9.6) 111 (10.3) 0.90 (0.66, 1.22) 362 (9.5) 162 (9.8) 0.90 (0.69, 1.16) 
2005 280 (10.0) 92 (8.5) 0.71 (0.52, 0.98)
†
 387 (10.3) 153 (9.2) 0.79 (0.61, 1.03)
*
 
2006 268 (9.5) 101 (9.4) 0.82 (0.60, 1.12) 380 (10.0) 176 (10.6) 0.93 (0.72, 1.20) 
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Average LOS per hospitalization > 7 days     
1997 229 (9.6) 103 (10.9) 1.00 263 (9.3) 129 (9.8) 1.00 
1998 244 (10.3) 110 (11.6) 1.00(0.73, 1.39) 289 (10.2) 147 (11.2) 1.04 (0.78, 1.39) 
1999 169 (11.3) 103 (10.9) 0.85 (0.62, 1.18) 319 (11.3) 151 (11.5) 0.97 (0.73, 1.29) 
2000 226 (9.5) 94 (10.0) 0.93 (0.66, 1.29) 272 (9.6) 127 (9.7) 0.95 (0.71, 1.28) 
2001 237 (10.0) 93 (9.8) 0.87 (0.63, 1.22) 271 (9.6) 138 (10.5) 1.04 (0.77, 1.39) 
2002 249 (10.5) 82 (8.7) 0.73 (0.52, 1.03)
 *
 292 (10.3) 113 (8.6) 0.79 (0.58, 1.07) 
2003 230 (9.7) 87 (9.2) 0.84 (0.60, 1.18) 294 (10.4) 127 (9.7) 0.88 (0.66, 1.18) 
2004 242 (10.2) 97 (10.3) 0.89 (0.64, 1.24) 267 (9.4) 130 (10.0) 0.99 (0.74, 1.34) 
2005 232 (9.8) 87 (9.2) 0.83 (0.59, 1.17) 292 (10.3) 109 (8.3) 0.76 (0.56, 1.03)
*
 
2006 220 (9.3) 89 (9.4) 0.90 (0.64, 1.26) 272 (9.6) 139 (10.6) 1.04 (0.78, 1.40) 
       
>2 Hospitalizations      
1997 244 (7.9) 124 (10.1) 1.00 87 (8.6) 41 (11.4) 1.00 
1998 305 (9.8) 118 (9.6) 0.78 (0.46, 1.34) 95 (9.4) 35 (9.7) 0.76 (0.56, 1.03)
*
 
1999 369 (11.9) 142 (11.6) 0.59 (0.35, 1.01)
*
 119 (11.7) 33 (9.2) 0.76 (0.57, 1.01)
*
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2000 318 (10.3) 127 (10.4) 0.75 (0.45, 1.27) 107 (10.5) 38 (10.6) 0.79 (0.58, 1.06) 
2001 314 (10.1) 118 (9.6) 0.54 (0.31, 0.94)
†
 110 (10.8) 28 (7.8) 0.74 (0.55, 1.00)
*
 
2002 318 (10.3) 115 (9.4) 0.76 (0.44, 1.30) 95 (9.4) 34 (9.4) 0.71 (0.53, 0.96)
†
 
2003 309 (10.0) 113 (9.2) 0.65 (0.38, 1.11) 108 (10.6) 33 (9.2) 0.72 (0.53, 0.98)
†
 
2004 297 (9.6) 120 (9.8) 1.04 (0.63, 1.72) 104 (10.2) 51 (14.2) 0.80 (0.59, 1.08) 
2005 321 (10.4) 114 (9.3) 0.73 (0.43, 1.25) 99 (9.7) 34 (9.4) 0.70 (0.52, 0.95)
†
 
2006 305 (9.8) 135 (11.0) 0.76 (0.44, 1.31) 92 (9.1) 33 (9.2) 0.87 (0.65, 1.17) 
* P<0.10 
† P<0.05 
‡ P<0.01 
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Calendar year was included in the logistic regression model as a main effect variable to 
investigate the trends of hospital service utilization (Total LOS in hospitals, Average LOS per 
hospitalization and number of hospitalizations) over the 10-year study period. In addition, 
calendar year was also included as a continuous variable in the model to examine the linear 
trends.  
 
As shown in Table 4.15, there was no statistically significant relationship observed between 
calendar year and the total LOS > 7 days in hospitals, which was also consistent with the results 
obtained from multivariate regression models regarding calendar year as a continuous variable 
[P=0.16 with OR (95%CI) = 0.99 (0.97, 1.01) in the 6 months prior to death and P=0.25 with OR 
(95%CI) = 0.99 (0.97, 1.01) in the last month of life].  
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Table 4.15 Multivariate Analysis examining associations with total LOS in hospital 
 Total LOS >7 days in Hospital 
in the 6 months prior to death 
Total LOS >7 days in Hospital 
in the 1 month prior to death 
 Adjusted OR 
(95%CI) 
P-value Adjusted OR 
(95%CI) 
P-value 
Disease status     
  Lung Cancer  1.00  1.00  
  COPD 0.63 (0.56, 0.72) <0.0001 0.61 (0.54, 0.68) <0.0001 
Calendar year     
  1997 1.00  1.00  
  1998 0.89 (0.68, 1.15) 0.39 0.95 (0.76, 1.19) 0.64 
  1999 0.99 (0.77, 1.29) 0.99 0.98 (0.79, 1.22) 0.86 
  2000 0.91 (0.70, 1.18) 0.47 0.92 (0.73, 1.15) 0.45 
  2001 0.81 (0.65, 1.09) 0.18 0.96 (0.76, 1.20) 0.71 
  2002 0.92 (0.71, 1.19) 0.52 0.99 (0.78, 1.24) 0.90 
  2003 0.82 (0.64, 1.06) 0.14 0.92 (0.73, 1.15) 0.47 
  2004 0.89 (0.68, 1.15) 0.37 1.07 (0.85, 1.35) 0.55 
  2005 0.87 (0.67, 1.13) 0.30 0.94 (0.75, 1.18) 0.58 
  2006 0.86 (0.66, 1.11) 0.24 0.80 (0.64, 1.00) 0.06 
Age      
  ≤59 years       1.00  1.00  
  60-69 years 1.15 (0.92, 1.44) 0.23 1.22 (1.01, 1.49) 0.04 
  70-79 years 1.20 (0.97, 1.49) 0.10 1.31 (1.09, 1.57) 0.005 
  80-89 years 0.92 (0.74, 1.15) 0.45 1.17 (0.96, 1.41) 0.12 
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  ≥90 years 0.76 (0.49, 1.18) 0.22 0.75 (0.49, 1.15) 0.19 
Sex     
  Female  1.00  1.00  
  Male 0.88 (0.78, 0.99) 0.03 0.98 (0.88, 1.09) 0.74 
Residence      
  ≥300,000 1.00  1.00  
  (10,000- 299,999) 0.99 (0.86, 1.17) 0.98 0.99 (0.86, 1.15) 0.94 
  <10,000 1.31 (1.16, 1.49) <0.0001 1.20 (1.07, 1.34) 0.002 
Comorbid Condition     
  0-1  1.00  1.00  
  ≥2 1.23 (1.10, 1.38) <0.0001 1.04 (0.94, 1.16) 0.41 
Location of Death     
  Hospital  1.00  1.00  
  Outside Hospital 0.55 (0.48, 0.62) <0.0001 0.25 (0.22, 0.28) <0.0001 
Marital Status     
  Married/ Common Law  1.00  1.00  
  Never Married 1.18 (0.95, 1.46) 0.14 1.29 (1.07, 1.55) 0.008 
  Separated/ Divorced 1.03 (0.89, 1.19) 0.69 1.11 (0.97, 1.26) 0.12 
  Widowed 0.91 (0.77, 1.07) 0.25 1.08 (0.93, 1.25) 0.34 
Institutional Services     
  No  1.00  1.00  
  Yes 1.31 (1.13, 1.53) 0.001 1.04 (0.91, 1.19) 0.57 
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Transfer within Institution     
  No  1.00  1.00  
  Yes  2.60 (1.85, 3.67) <0.0001 0.50 (0.38, 0.66) <0.0001 
Adjusted for all the variables in the table. 
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Table 4.16 provides the multivariate analysis investigating associations with calendar year and 
the Average LOS per hospitalization. In the six months prior to death, reductions in the hospital 
usage were observed in 2003 (OR= 0.79, 95%CI= 0.64-0.99), 2005 (OR= 0.79, 95%CI= 0.64-
0.99), 2006 (OR=0.76, 95%CI=0.61-0.95) as compared to that in 1997. The regression model 
examining the linear effect of calendar year also showed a reduced OR (OR= 0.97, 95%CI= 
0.96-0.99) with P-value equals 0.001. In the last month of life, fewer decedents had longer 
hospital stay per visit in 2003 (OR=0.77, 95%CI=0.68-0.96) and in 2006 (OR=0.73, 95%CI= 
0.58-0.91) when compared with that in 1997. However, the multivariate analysis regarding 
calendar year as a continuous variable presents a non-significant result [OR (95%CI) = 0.99 
(0.97, 1.00) with P=0.11].  
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Table 4.16 Multivariate Analysis examining associations with average LOS per hospitalization 
 Average LOS >7 days in 
Hospital in the 6 months prior to 
death 
Average LOS >7 days in 
Hospital in the 1 month prior to 
death 
 Adjusted OR 
(95%CI) 
P-value Adjusted OR 
(95%CI) 
P-value 
Disease status     
  Lung Cancer  1.00  1.00  
  COPD 0.78 (0.70, 0.87) <0.0001 0.67 (0.60, 0.75) <0.0001 
Calendar year     
  1997 1.00  1.00  
  1998 1.03 (0.82, 1.29) 0.80 0.92 (0.74, 1.15) 0.45 
  1999 0.90 (0.73, 1.12) 0.35 0.86 (0.69, 1.07) 0.17 
  2000 0.84 (0.67, 1.05) 0.12 0.82 (0.66, 1.02) 0.08 
  2001 0.82 (0.65, 1.02) 0.07 0.86 (0.67, 1.07) 0.17 
  2002 0.87 (0.69, 1.09) 0.22 0.94 (0.75, 1.18) 0.59 
  2003 0.79 (0.64, 0.99) 0.04 0.77 (0.68, 0.96) 0.02 
  2004 0.84 (0.67, 1.05) 0.13 1.06 (0.84, 1.33) 0.63 
  2005 0.79 (0.64, 0.99) 0.04 0.87 (0.69, 1.09) 0.22 
  2006 0.76 (0.61, 0.95) 0.02 0.73 (0.58, 0.91) 0.006 
Age      
  ≤59 years       1.00  1.00  
  60-69 years 1.22 (1.01, 1.47) 0.04 1.15 (0.95, 1.39) 0.16 
  70-79 years 1.39 (1.16, 1.66) <0.0001 1.34 (1.11, 1.60) 0.002 
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  80-89 years 1.17 (0.97, 1.41) 0.11 1.21 (1.00, 1.46) 0.05 
  ≥90 years 1.02 (0.68, 1.54) 0.92 0.79 (0.51, 1.22) 0.30 
Sex     
  Female  1.00  1.00  
  Male 0.85 (0.77, 0.94) 0.002 1.01 (0.91, 1.12) 0.91 
Residence      
  ≥300,000 1.00  1.00  
  (10,000- 299,999) 1.14 (0.99, 1.32) 0.06 1.13 (0.98, 1.30) 0.10 
  <10,000 1.17 (1.05, 1.30) 0.005 1.17 (1.04, 1.30) 0.007 
Comorbid Condition     
  0-1  1.00  1.00  
  ≥2 1.83 (1.66, 2.02) <0.0001 1.23 (1.12, 1.37) <0.0001 
Location of Death     
  Hospital  1.00  1.00  
  Outside Hospital 0.63 (0.56, 0.71) <0.0001 0.30 (0.26, 0.33) <0.0001 
Marital Status     
  Married/ Common Law  1.00  1.00  
  Never Married 1.33 (1.11, 1.59) 0.002 1.36 (1.13. 1.63) 0.001 
  Separated/ Divorced 1.10 (0.97, 1.25) 0.15 1.20 (1.06, 1.36) 0.005 
  Widowed 1.04 (0.90, 1.20) 0.64 1.15 (0.99, 1.33) 0.07 
Institutional supportive care services    
  No  1.00  1.00  
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  Yes 1.52 (1.33, 1.74) <0.0001 1.11 (0.98, 1.26) 0.14 
Transfers between institutional supportive care facilities   
  No  1.00  1.00  
  Yes  2.60 (1.95, 3.47) <0.0001 0.48 (0.36, 0.64) <0.0001 
Adjusted for all the variables in the table. 
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Table 4.17 presents the result of the multivariate analysis investigating associations with 
calendar year and number of hospitalizations. In the six months prior to death, increased 
likelihood of frequent hospital admissions were observed in 1999 (OR=1.50, 95%CI=1.20-1.87), 
2000 (OR=1.51, 95%CI=1.20-1.90), 2002 (OR=1.47, 95%CI= 1.16-1.83), 2004 (OR=1.37, 
95%CI=1.09-1.72), 2005 (OR=1.41, 95%CI=1.12-1.77) and 2006 (OR=1.34, 95%CI=1.07-1.67) 
as compared with that in 1997. The multivariate analysis regarding calendar year as a continuous 
variable presents a non-significant result [OR (95%CI) = 1.02 (1.00, 1.04) with P=0.06]. In the 
last month of life, increased likelihood of frequent hospital admissions was observed in 2004 
(OR=1.41, 95%CI= 1.07-1.85). Again, the multivariate analysis regarding calendar year as a 
continuous variable presents a non-significant result [OR (95%CI) =1.02 (0.99, 1.04) with 
P=0.16]. 
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Table 4.17 Multivariate Analysis examining associations with Number of Hospitalizations 
 ≥ 2 hospitalizations in the 6 
months prior to death  
≥ 2 hospitalizations in the 1 
month prior to death 
 Adjusted OR 
(95%CI) 
P-value Adjusted OR 
(95%CI) 
P-value 
Disease status     
  Lung Cancer  1.00  1.00  
  COPD 0.72 (0.64, 0.80) <0.0001 0.81 (0.70, 0.93) 0.003 
Calendar year     
  1997 1.00  1.00  
  1998 1.16 (0.92, 1.45) 0.21 0.89 (0.68, 1.18) 0.43 
  1999 1.50 (1.20, 1.87) <0.0001 0.99 (0.77, 1.31) 0.99 
  2000 1.51 (1.20, 1.90) <0.0001 1.15 (0.87, 1.50) 0.33 
  2001 1.23 (0.98, 1.54) 0.08 1.04 (0.79, 1.37) 0.80 
  2002 1.47 (1.16, 1.83) 0.001 1.04 (0.78, 1.37) 0.80 
  2003 1.23 (0.98, 1.54) 0.07 1.13 (0.86, 1.49) 0.37 
  2004 1.37 (1.09, 1.72) 0.008 1.41 (1.07, 1.85) 0.01 
  2005 1.41 (1.12, 1.77) 0.003 1.10 (0.83, 1.45) 0.52 
  2006 1.34 (1.07, 1.67) 0.01 0.94 (0.71, 1.24) 0.64 
Age      
  ≤59 years       1.00  1.00  
  60-69 years 0.84 (0.68, 1.03) 0.10 0.87 (0.70, 1.09) 0.23 
  70-79 years 0.75 (0.62, 0.92) 0.005 0.83 (0.68, 1.03) 0.09 
  80-89 years 0.53 (0.43, 0.65) <0.0001 0.62 (0.50, 0.78) <0.0001 
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  ≥90 years 0.42 (0.28, 0.64) <0.0001 0.49 (0.27, 0.90) 0.02 
Sex     
  Female  1.00  1.00  
  Male 1.01 (0.90, 1.12) 0.92 1.19 (1.04, 1.35) 0.01 
Residence      
  ≥300,000 1.00  1.00  
  (10,000- 299,999) 0.93 (0.81, 1.08) 0.35 1.05 (0.87, 1.26) 0.61 
  <10,000 1.16 (1.04, 1.30) 0.009 1.42 (1.24, 1.64) <0.0001 
Comorbid Condition     
  0-1  1.00  1.00  
  ≥2 0.41 (0.37, 0.45) <0.0001 0.64 (0.57, 0.72) <0.0001 
Location of Death     
  Hospital  1.00  1.00  
  Outside Hospital 0.53 (0.46, 0.59) <0.0001 0.36 (0.30, 0.43) <0.0001 
Marital Status     
  Married/ Common Law  1.00  1.00  
  Never Married 0.64 (0.53, 0.76) <0.0001 0.89 (0.71, 1.11) 0.31 
  Separated/ Divorced 0.91 (0.80, 1.04) 0.16 0.97 (0.83, 1.13) 0.68 
  Widowed 0.86 (0.74, 0.99) 0.04 0.98 (0.82, 1.19) 0.86 
Institutional supportive care services    
  No  1.00  1.00  
  Yes 1.10 (0.96, 1.26) 0.16 0.81 (0.68, 0.97) 0.02 
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Transfers between institutional supportive care facilities   
  No  1.00  1.00  
  Yes  1.39 (1.08, 1.78) 0.01 0.81 (0.53, 1.26)  0.35 
Adjusted for all the variables in the table. 
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Table 4.18, 4.19 and 4.20 present the results of the analysis stratified by disease status to 
investigate whether it is an effect modifier in the relationship between calendar year and the 
dependent variables (total LOS greater than 7 days, average LOS per visit greater than 7 days, 
and more than 2 hospitalizations).  
 
The overall Likelihood Ratio test was used to confirm the inclusion of the interaction in the 
regression model. As shown in Table 4.18, disease status is not an effect modifier in the 
association between calendar year and Total LOS greater than 7 days in hospitals in the six 
months prior to death (P = 0.57 with log-likelihood difference=7.607 for 8 d.f.). Disease status 
does not significantly influence the relationship between calendar year and Total LOS greater 
than 7 days in hospitals in the last month of life (P=0.69 with log-likelihood difference= 6.477 
for 9 d.f.).  
 
As shown in Table 4.19, disease status is not an effect modifier in the association between 
calendar year and Average LOS per visit greater 7 days in the six months prior to death (P =0.09 
with log-likelihood difference= 15.075 for 9 d.f.). Disease status does not significantly affect the 
relationship between calendar year and Average LOS per visit greater 7 days in the last one 
month of life (P=0.71 with log-likelihood difference= 6.302 for 9 d.f.).  
 
As shown in Table 4.20, disease status modify the association between calendar year and number 
of hospitalizations in the six months prior to death (P=0.45 with log-likelihood difference= 8.865 
for 9 d.f.). Disease status is not an effect modifier in the relationship between calendar year and 
number of hospitalizations in the last month of life (P =0.37 with log-likelihood difference= 
9.805 for 9 d.f.).  
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Table 4.18 Association between disease status and total LOS in hospital stratified by disease 
status  
 Total LOS >7 days in Hospital in the 6 
months prior to death 
Total LOS >7 days in Hospital in the 1 
month prior to death 
 Adjusted OR 
(95%CI) 
 Adjusted OR 
(95%CI) 
 
Calendar Year COPD Lung Cancer COPD Lung Cancer 
  1998 0.98 (0.64, 1.50) 0.82 (0.59, 1.14) 1.02 (0.70, 1.50) 0.89 (0.67, 1.18) 
  1999 1.08 (0.71, 1.65) 0.95 (0.69, 1.32) 0.94 (0.65, 1.37) 0.99 (0.75, 1.30) 
  2000 0.81 (0.53, 1.23) 0.98 (0.70, 1.37) 0.80 (0.655, 1.17) 1.98 (0.73, 1.31) 
  2001 0.70 (0.47, 1.05) 0.93 (0.66, 1.29) 0.81 (0.56, 1.18) 1.04 (0.78, 1.38) 
  2002 0.82 (0.53, 1.23) 0.97 (0.70, 1.35) 0.89 (0.60, 1.32) 1.04 (0.78, 1.38) 
  2003 0.66 (0.44, 1.00) 0.93 (0.67, 1.29) 0.80 (0.55, 1.17) 0.98 (0.74, 1.30) 
  2004 0.78 (0.51, 1.19) 0.95 (0.68, 1.32) 1.02 (0.69, 1.50) 1.10 (0.83, 1.47) 
  2005 0.70 (0.46, 1.06) 0.98 (0.71, 1.37) 0.73 (0.49, 1.08) 1.06 (0.80, 1.40) 
  2006 0.74 (0.49, 1.11) 0.93 (0.67, 1.30) 0.68
 
(0.46, 1.00)
 *
 0.86 (0.65, 1.15) 
Adjusted for age, sex, residence, comorbid condition, marital status, location of death, institutional supportive care 
services and transfers between institutional supportive care facilities. 
 
Table 4.19 Association between disease status and average LOS per hospitalization stratified by 
disease status  
 Average LOS per visit >7 days in the 6 
months prior to death 
Average LOS per visit > 7days in the 1 
month prior to death 
 Adjusted OR 
(95%CI) 
 Adjusted OR 
(95%CI) 
 
Calendar Year COPD Lung Cancer COPD Lung Cancer 
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  1998 1.34 (0.91, 1.97)
 +
 0.88 (0.67, 1.16) 1.14 (0.78, 1.67) 0.81
 
(0.61, 1.06) 
  1999 1.12 (0.77, 1.63) 0.80 (0.61, 1.04) 0.89 (0.61, 1.30) 0.83 (0.64, 1.08) 
  2000 0.78 (0.54, 1.14) 0.85 (0.64, 1.13) 0.77 (0.52, 1.13) 0.84 (0.63, 1.10) 
  2001 0.89 (0.62, 1.30) 0.75 (0.57, 0.99) 0.75 (0.51, 1.10) 0.90 (0.68, 1.18) 
  2002 0.80 (0.54, 1.19) 0.87 (0.66, 1.15) 0.89 (0.59, 1.32) 0.95 (0.73, 1.25) 
  2003 0.72 (0.50, 1.06) 0.81 (0.61, 1.07) 0.74 (0.50, 1.09) 0.78 (0.59, 1.02) 
  2004 0.90 (0.61, 1.32) 0.79 (0.60, 1.05) 1.01 (0.69, 1.50) 1.08
 
(0.82, 1.43) 
  2005 0.65 (0.44, 0.95) 0.85 (0.65, 1.12) 0.86 (0.58, 1.27) 0.86 (0.66, 1.13) 
  2006 0.80
 
(0.55, 1.17) 0.72 (0.55, 0.95) 0.71 (0.48, 1.04) 0.73 (0.55, 0.96) 
Adjusted for age, sex, residence, comorbid condition, marital status, location of death, institutional supportive care 
services and transfers between institutional supportive care facilities. 
 
Table 4.20 Association between disease status and number of hospitalizations stratified by 
disease status 
 >2 Hospitalizations in the 6 months prior to 
death 
>2 Hospitalizations in the 1 month prior to 
death 
 Adjusted OR 
(95%CI) 
 Adjusted OR 
(95%CI) 
 
Calendar Year COPD Lung Cancer COPD Lung Cancer 
  1998 0.96 (0.66, 1.41) 1.29 (0.98, 1.71) 0.79 (0.47, 1.31) 0.90 (0.54, 1.49) 
  1999 1.25 (0.85, 1.82) 1.68 (1.28, 2.21) 0.89 (0.54, 1.47) 0.74 (0.44, 1.24) 
  2000 1.10 (0.75, 1.61) 1.81 (1.36, 2.42)
 *
 0.77 (0.46, 1.28) 0.94 (0.57, 1.55) 
  2001 0.87 (0.60, 1.27) 1.50 (1.13, 2.00)
 *
 0.97 (0.59, 1.58) 1.67 (0.39, 1.14) 
  2002 1.18 (0.80, 1.75) 1.63 (1.23, 2.16) 0.64 (0.38, 1.09) 1.02 (0.61, 1.71) 
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  2003 0.87 (0.59, 1.27) 1.49 (1.13, 1.97)
 *
 0.99 (0.59, 1.65) 0.88 (0.52, 1.47)
 *
 
  2004 1.01 (0.68, 1.48) 1.62 (1.22, 2.15)
 *
 0.87 (0.52, 1.45) 1.45 (0.89, 2.35) 
  2005 0.96 (0.65, 1.41) 1.76 (1.33, 2.33)
 *
 1.41 (0.88, 2.27) 0.90 (0.53, 1.51) 
  2006 1.10 (0.75, 1.61) 1.50 (1.13, 1.99) 0.86 (0.52, 1.44) 0.78 (0.46, 1.30) 
Adjusted for age, sex, residence, comorbid condition, marital status, location of death, institutional supportive care 
services and transfers between institutional supportive care facilities. 
 
4.4 Sensitivity analysis  
Table 4.21 presents the result of sensitivity analysis regarding the association between all the 
variables included with hospitalization (total LOS>7days, average LOS>7days and number of 
hospitalizations) after re-categorizing the variables Institutional Services and Transfer within 
Institution into a new variable (no institutional care and no transfer, institutional care without 
transfer and institutional care with transfer) in the last six months of life. The result shows that, 
among the three models, the odds ratio for each variable included in the model does not change 
significantly compared to the original model 
 
Table 4.21 Sensitivity analysis Multivariate Analysis examining associations with hospital 
service utilization 
 Total LOS >7 days in Hospital 
in the 6 months prior to death  
Average LOS>7 days per 
visit in the 6 months prior 
to death  
≥ 2 hospitalizations in the 
6 months prior to death  
 Adjusted OR 
(95%CI) 
P-value Adjusted 
OR 
(95%CI) 
P-value Adjusted 
OR 
(95%CI) 
P-value 
Disease status      
  Lung Cancer  1.00  1.00  1.00 
  COPD 0.63 (0.56, <0.0001 0.78 (0.70, <0.0001 0.72 (0.64, <0.0001 
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0.72) 0.87) 0.80) 
Calendar year       
  1997 1.00  1.00  1.00  
  1998 0.89 (0.67, 
1.15) 
0.36 1.03 (0.82, 
1.29) 
0.80 1.16 (0.92, 
1.45) 
0.21 
  1999 1.00 (0.77, 
1.29) 
0.99 0.90 (0.73, 
1.12) 
0.35 1.50 (1.20, 
1.87) 
<0.0001 
  2000 0.91 (0.70, 
1.18) 
0.47 0.84 (0.67, 
1.05) 
0.12 1.51 (1.20, 
1.90) 
<0.0001 
  2001 0.84 (0.65, 
1.08) 
0.18 0.82 (0.65, 
1.02) 
0.07 1.23 (0.98, 
1.54) 
0.08 
  2002 0.92 (0.71, 
1.19) 
0.52 0.87 (0.69, 
1.09) 
0.21 1.47 (1.16, 
1.83) 
0.001 
  2003 0.82 (0.64, 
1.06) 
0.14 0.79 (0.64, 
0.99) 
0.04 1.23 (0.98, 
1.54) 
0.07 
  2004 0.89 (0.68, 
1.15) 
0.37 0.84 (0.67, 
1.05) 
0.13 1.37 (1.09, 
1.72) 
0.008 
  2005 0.87 (0.67, 
1.13) 
0.30 0.79 (0.64, 
0.99) 
0.04 1.41 (1.12, 
1.77) 
0.003 
  2006 0.86 (0.66, 111) 0.24 0.76 (0.61, 
0.95) 
0.02 1.34 (1.07, 
1.67) 
0.01 
Age        
  ≤59 years       1.00  1.00  1.00  
  60-69 years 1.15 (0.92, 
1.44) 
0.23 1.22 (1.01, 
1.47) 
0.04 0.84 (0.68, 
1.03) 
0.10 
  70-79 years 1.20 (0.97, 0.10 1.39 (1.16, <0.0001 0.75 (0.62, 0.005 
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1.49) 1.66) 0.92) 
  80-89 years 0.92 (0.74, 
1.15) 
0.45 1.17 (0.97, 
1.41) 
0.11 0.53 (0.43, 
0.65) 
<0.0001 
  ≥90 years 0.76 (0.49, 
1.18) 
0.22 1.02 (0.68, 
1.54) 
0.92 0.42 (0.28, 
0.64) 
0.005 
Sex       
  Female  1.00  1.00  1.00  
  Male 0.88 (0.77, 
0.99) 
0.03 0.85 (0.77, 
0.94) 
0.002 1.01 (0.90, 
1.12) 
0.90 
Residence        
  ≥300,000 1.00  1.00  1.00  
  (10,000- 299,999) 1.00 (0.86, 
1.17) 
0.98 1.14 (0.99, 
1.32) 
0.06 0.93 (0.81, 
1.08) 
0.61 
  <10,000 1.31 (1.16, 
1.49) 
<0.0001 1.17 (1.05, 
1.30) 
0.005 1.16 (1.04, 
1.30) 
0.008 
Comorbid Condition       
  0-1  1.00  1.00  1.00  
  ≥2 1.23 (1.10, 
1.38) 
<0.0001 1.83 (1.66, 
2.02) 
<0.0001 0.41 (0.37, 
0.45) 
<0.0001 
Location of Death       
  Hospital  1.00  1.00  1.00  
  Outside Hospital 0.55 (0.48, 
0.62) 
<0.0001 0.63 (0.56, 
0.71) 
<0.0001 0.53 (0.46, 
0.59) 
<0.0001 
Marital Status       
  Married/ Common Law  1.00  1.00  1.00  
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  Never Married 1.18 (0.95, 
1.46) 
0.14 1.33 (1.11, 
1.59) 
0.002 0.64 (0.53, 
0.76) 
<0.0001 
  Separated/ Divorced 1.03 (0.89, 
1.19) 
0.69 1.10 (0.97, 
1.25) 
0.15 0.91 (0.80, 
1.04) 
0.16 
  Widowed 0.91 (0.77, 
1.07) 
0.26 1.04 (0.90, 
1.20) 
0.64 0.86 (0.74, 
0.99) 
0.04 
Transfer within 
Institution 
      
No institutional care and 
no transfer 
1.00   1.00  1.00  
Institutional care without 
transfer  
1.31 (1.13, 
1.53) 
0.001 1.52 (1.33, 
1.74) 
<0.0001 1.10 (0.96, 
1.26) 
0.16 
Institutional care with 
transfer  
3.41 (2.43, 
4.79) 
<0.0001 3.96 (2.97, 
5.27) 
<0.0001 1.52 (1.19, 
1.95) 
<0.0001 
 
Table 4.22 presents the result of sensitivity analysis regarding the association with total LOS in 
hospital in the last six months of life (total LOS>7 days, total LOS>3 days and total LOS>14 
days). The result shows that, among the three models, the odds ratio for each variable included in 
the model does not change significantly. 
 
Table 4.22 Sensitivity Analysis examining associations with total LOS in hospital 
 Total LOS >7 days in 
Hospital in the 6 months 
prior to death 
Total LOS >3 days in 
Hospital in the 6 months 
prior to death 
Total LOS >14 days in 
Hospital in the 6 months 
prior to death 
 Adjusted OR 
(95%CI) 
P-value Adjusted OR 
(95%CI) 
P-value Adjusted 
OR 
(95%CI) 
P-value 
Disease status      
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  Lung Cancer  1.00  1.00  1.00  
  COPD 0.63 (0.56, 
0.72) 
<0.0001 0.65 (0.55, 
0.76) 
<0.0001 0.67 (0.60, 
0.75) 
<0.0001 
Calendar year      
  1997 1.00  1.00  1.00 
  1998 0.89 (0.68, 
1.15) 
0.39 1.11 (0.79, 
1.55) 
0.56 1.01 (0.81, 
1.26) 
0.95 
  1999 0.99 (0.77, 
1.29) 
0.99 1.02 (0.74, 
1.41) 
0.92 0.92 (0.74, 
1.14) 
0.45 
  2000 0.91 (0.70, 
1.18) 
0.47 1.01 (0.72, 
1.42) 
0.95 1.02 (0.82, 
1.28) 
0.85 
  2001 0.81 (0.65, 
1.09) 
0.18 0.95 (0.68, 
1.31) 
0.74 0.81 (0.65, 
1.01) 
0.07 
  2002 0.92 (0.71, 
1.19) 
0.52 1.09 (0.77, 
1.53) 
0.63 0.90 (0.72, 
1.12) 
0.35 
  2003 0.82 (0.64, 
1.06) 
0.14 0.93 (0.67, 
1.29) 
0.65 0.88 (0.71, 
1.10) 
0.26 
  2004 0.89 (0.68, 
1.15) 
0.37 1.07 (0.76, 
1.50) 
0.71 0.97 (0.77, 
1.21) 
0.77 
  2005 0.87 (0.67, 
1.13) 
0.30 0.99 (0.71, 
1.38) 
0.97 0.85 (0.68, 
1.06) 
0.16 
  2006 0.86 (0.66, 
1.11) 
0.24 0.87 (0.63, 
1.20) 
0.40 0.86 (0.69, 
1.07) 
0.19 
Age       
  ≤59 years       1.00  1.00  1.00 
  60-69 years 1.15 (0.92, 0.23 1.09 (0.80, 0.58 1.17 (0.97, 0.11 
   
 
 
 
112 
1.44) 1.48) 1.42) 
  70-79 years 1.20 (0.97, 
1.49) 
0.10 1.11 (0.83, 
1.48) 
0.48 1.15 (0.96, 
1.38) 
0.13 
  80-89 years 0.92 (0.74, 
1.15) 
0.45 0.84 (0.62, 
1.12) 
0.24 0.90 (0.74, 
1.09) 
0.27 
  ≥90 years 0.76 (0.49, 
1.18) 
0.22 0.59 (0.34, 
1.02) 
0.06 0.62 (0.42, 
0.94) 
0.02 
Sex      
  Female  1.00  1.00  1.00 
  Male 0.88 (0.78, 
0.99) 
0.03 0.84 (0.72, 
0.99) 
0.04 0.84 (0.75, 
0.93) 
<0.0001 
Residence       
  ≥300,000 1.00  1.00  1.00 
  (10,000- 299,999) 0.99 (0.86, 
1.17) 
0.98 1.11 (0.90, 
1.36) 
0.34 1.09 (0.95, 
1.26) 
0.22 
  <10,000 1.31 (1.16, 
1.49) 
<0.0001 1.40 (1.19, 
1.66) 
<0.0001 1.22 (1.10, 
1.36) 
<0.0001 
Comorbid Condition      
  0-1  1.00  1.00  1.00 
  ≥2 1.23 (1.10, 
1.38) 
<0.0001 1.60 (1.38, 
1.85) 
<0.0001 1.12 (1.01, 
1.24) 
0.03 
Location of Death      
  Hospital  1.00  1.00  1.00 
  Outside Hospital 0.55 (0.48, 
0.62) 
<0.0001 0.52 (0.44, 
0.61) 
<0.0001 0.50 (0.44, 
0.56) 
<0.0001 
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Marital Status      
  Married/ Common 
Law  
1.00  1.00  1.00 
  Never Married 1.18 (0.95, 
1.46) 
0.14 1.16 (0.87, 
1.53) 
0.31 1.20 (1.00, 
1.43) 
0.05 
  Separated/ Divorced 1.03 (0.89, 
1.19) 
0.69 1.12 (0.92, 
1.36) 
0.24 1.05 (0.93, 
1.19) 
0.46 
  Widowed 0.91 (0.77, 
1.07) 
0.25 0.96 (0.77, 
1.18) 
0.67 0.96 (0.83, 
1.11) 
0.57 
Institutional Services      
  No  1.00  1.00  1.00 
  Yes 1.31 (1.13, 
1.53) 
0.001 1.29 (1.06, 
1.57) 
0.01 1.60 (1.40, 
1.83) 
<0.0001 
Transfer within 
Institution 
     
  No  1.00  1.00  1.00 
  Yes  2.60 (1.85, 
3.67) 
<0.0001 2.45 (1.55, 
3.86) 
<0.0001 3.12 (2.34, 
4.16) 
<0.0001 
 
 
Table 4.23 presents the result of sensitivity analysis regarding the association with average LOS 
per visit in the last six months of life (average LOS>7 days, average LOS>3 days and average 
LOS>14 days). Among the three models, the result shows that the odds ratio for each variable 
included in the model does not change significantly except for calendar year. A reduced odds 
ratio is observed in the logistic regression model examining associations with average LOS per 
hospitalization greater than 14 days.  
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Table 4.23 Sensitivity Analysis examining associations with Average LOS per hospitalization 
 Average LOS >7 days in 
Hospital in the 6 months 
prior to death 
Average LOS >3 days in 
Hospital in the 6 months 
prior to death 
Average LOS >14 days 
in Hospital in the 6 
months prior to death 
 Adjusted OR 
(95%CI) 
P-value Adjusted OR 
(95%CI) 
P-value Adjusted 
OR 
(95%CI) 
P-value 
Disease status      
  Lung Cancer  1.00  1.00  1.00 
  COPD 0.78 (0.70, 
0.87) 
<0.0001 0.82 (0.72, 
0.95) 
0.006 0.73 (0.65, 
0.83) 
<0.0001 
Calendar year      
  1997 1.00  1.00  1.00 
  1998 1.03 (0.82, 
1.29) 
0.80 1.02 (0.76, 
1.36) 
0.89 0.92 (0.73, 
1.16) 
0.48 
  1999 0.90 (0.73, 
1.12) 
0.35 0.95 (0.72, 
1.26) 
0.74 0.77 (0.61, 
0.97) 
0.03 
  2000 0.84 (0.67, 
1.05) 
0.12 0.94 (0.71, 
1.26) 
0.69 0.72 (0.57, 
0.91) 
0.006 
  2001 0.82 (0.65, 
1.02) 
0.07 0.89 (0.67, 
1.18) 
0.41 0.60 (0.47, 
0.77) 
<0.0001 
  2002 0.87 (0.69, 
1.09) 
0.22 0.94 (0.71, 
1.26) 
0.69 0.62 (0.48, 
0.78) 
<0.0001 
  2003 0.79 (0.64, 
0.99) 
0.04 0.93 (0.70, 
1.24) 
0.61 0.70 (0.55, 
0.88) 
0.003 
  2004 0.84 (0.67, 
1.05) 
0.13 1.04 (0.78, 
1.40) 
0.78 0.66 (0.52, 
0.84) 
0.001 
  2005 0.79 (0.64, 0.04 0.87 (0.66, 0.35 0.70 (0.55, 0.003 
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0.99) 1.16) 0.89) 
  2006 0.76 (0.61, 
0.95) 
0.02 0.89 (0.67, 
1.19) 
0.44 0.69 (0.55, 
0.88) 
0.002 
Age       
  ≤59 years       1.00  1.00  1.00 
  60-69 years 1.22 (1.01, 
1.47) 
0.04 1.24 (0.98, 
1.58) 
0.08 1.13 (0.92, 
1.39) 
0.26 
  70-79 years 1.39 (1.16, 
1.66) 
<0.0001 1.30 (1.04, 
1.64) 
0.02 1.12 (0.92, 
1.37) 
0.26 
  80-89 years 1.17 (0.97, 
1.41) 
0.11 1.13 (0.89, 
1.44) 
0.31 0.98 (0.80, 
1.21) 
0.86 
  ≥90 years 1.02 (0.68, 
1.54) 
0.92 0.82 (0.50, 
1.34) 
0.42 0.86 (0.55, 
0.88) 
0.51 
Sex      
  Female  1.00  1.00  1.00 
  Male 0.85 (0.77, 
0.94) 
0.002 0.86 (0.75, 
0.98) 
<0.0001 0.78 (0.70, 
0.87) 
<0.0001 
Residence       
  ≥300,000 1.00  1.00  1.00 
  (10,000- 299,999) 1.14 (0.99, 
1.32) 
0.06 1.06 (0.89, 
1.26) 
0.53 1.11 (0.96, 
1.30) 
0.17 
  <10,000 1.17 (1.05, 
1.30) 
0.005 1.30 (1.13, 
1.50) 
<0.0001 1.06 (0.94, 
1.19) 
0.35 
Comorbid Condition      
  0-1  1.00  1.00  1.00 
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  ≥2 1.83 (1.66, 
2.02) 
<0.0001 1.85 (1.63, 
2.10) 
<0.0001 1.85 (1.66, 
2.07) 
<0.0001 
Location of Death      
  Hospital  1.00  1.00  1.00 
  Outside Hospital 0.63 (0.56, 
0.71) 
<0.0001 0.62 (0.53, 
0.72) 
<0.0001 0.63 (0.55, 
0.72) 
<0.0001 
Marital Status      
  Married/ Common 
Law  
1.00  1.00  1.00 
  Never Married 1.33 (1.11, 
1.59) 
0.002 1.33 (1.03, 
1.70) 
0.03 1.47 (1.22, 
1.78) 
<0.0001 
  Separated/ Divorced 1.10 (0.97, 
1.25) 
0.15 1.05 (0.89, 
1.24) 
0.55 1.16 (1.01, 
1.33) 
0.03 
  Widowed 1.04 (0.90, 
1.20) 
0.64 0.94 (0.78, 
1.13) 
0.50 1.21 (1.03, 
1.41) 
0.02 
Institutional supportive care services     
  No  1.00  1.00  1.00 
  Yes 1.52 (1.33, 
1.74) 
<0.0001 1.36 (1.15, 
1.62) 
<0.0001 1.81 (1.57, 
2.08) 
<0.0001 
Transfers between institutional supportive care facilities    
  No  1.00  1.00  1.00 
  Yes  2.60 (1.95, 
3.47) 
<0.0001 2.10 (1.41, 
3.14) 
<0.0001 2.65 (2.06, 
3.40) 
<0.0001 
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Chapter 5: DISCUSSION 
 
In total, 7,114 subjects were included in this study using data from Saskatchewan Health, with 
2,332 decedents from COPD and 4,782 decedents from lung cancer. Retrospective data 
collection was used in the current study due to the difficulty in identifying patients who were at 
high risk of dying within six months in a prospective study as well as in having the ability, 
through the use of Saskatchewan Health data, to identify those who died from the conditions of 
interest and being able to look back in time. Half of the decedents were rural dwellers, and were 
married or common law. The majority had multiple comorbid conditions, died in hospitals, and 
had never received services from long-term supportive care institutions.  
 
5.1 Summary and interpretation of results 
5.1.1 Disease Status 
The results of the current study were similar to earlier reports where decedents from lung cancer 
were more likely to utilize hospital services, but less likely to receive ICU care than their COPD 
counterparts [47, 56, 58]. Many factors could provide an explanation for this difference between 
the disease groups. One potential reason could be the great variability in COPD progression, 
making the prognosis a great challenge for physicians. According to an UK study from Gardiner 
and colleagues in 2009, for those later found to be in their last week of life, their physicians had 
estimated a forty percent likelihood of six or more months of survival [92]. Apart from the 
unpredictable disease prognosis, physicians in the United States also found it difficult to start the 
end-of-life discussions with patients suffering from end-stage COPD as compared with those 
living with advanced lung cancer [41]. According to Knauft and colleagues, approximately three 
quarters of the patients would rather talk about staying alive than dying [41]. 
 
It was observed in this study that COPD patients were more likely to receive management in 
intensive care settings and have transfers between long-term care institutions, but were less likely 
to have frequent hospital admissions than their lung cancer counterparts. A possible 
interpretation was that the use of long-term care services was not mainly associated with the 
medical diagnostic category but was relevant to the functional status, such as impairment of daily 
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functioning, which was previously shown in other studies in health care utilization [47, 93].  In 
addition, lack of adequate patient education and discussion about preferences regarding end-of-
life care also made the COPD population more likely to be admitted to ICU due to exacerbations, 
which was supported by earlier research from Curtis and colleagues in the U.S. in 2002 [90].   
 
Our finding that the COPD population was more likely to use ICU services compared to the lung 
cancer population in both six months and one month prior to death were consistent with a prior  
U.S. study in 2002 [56], although the overall use of ICU was relatively low for both groups. The 
observed differences in ICU usage could be a result from differences in severity of illness or the 
difficulty of prognostic accuracy; unfortunately, we were not able to assess these factors in 
administrative data. Furthermore, expansion in the use of hospice care might also contribute to 
the lower proportion of lung cancer patients using aggressive care services, such as ICU [59]. 
Earle and colleagues, in 2004, found that individuals residing in regions with greater access to 
hospice services had a reduced likelihood of being admitted to intensive care settings at the end 
of life in the U.S. [81]. Our data was in line with an earlier UK report in 2000 where the COPD 
population was a more disadvantaged group in terms of medical and social care when compared 
with the lung cancer group [42].  
 
Given the expensive nature of ICU care, these results have large implications in terms of health 
care costs, especially considering the increased occurrence of COPD in the elderly population 
[94]. An earlier U.S. report in 2004 also suggested an improvement in the accessibility of 
palliative care services among the COPD population, which was a better alternative to 
unnecessary ICU use in terms of symptom relief and cost saving [81]. Improved accessibility of 
palliative service programs among the COPD population would increase the efficiency and value 
of services provided and would potentially be cost-saving. Importantly, improved access would 
lead to improved patients outcomes, both physical and psychosocial, and likely a reduction in 
avoidable ICU admission.  
 
   
119 
 
5.1.2 Age 
As expected, the proportion of COPD deaths increased with age except for the oldest age group 
(Table 1). As cited by Mannino and colleagues, the prevalence of COPD would double per 10-
year increase in age in the U.S. [18]. 
 
Our study, combined with earlier reports [2, 95], suggested that patients dying from lung cancer 
were on average younger than those dying from COPD. This observation could partially explain 
the finding that the COPD population was more likely to be managed in long-term care facilities 
as compared with their lung cancer counterparts since the supportive care services were more 
likely to be allocated to the elder population. 
 
We also found an increased likelihood of a longer hospital stay with increasing age up to a 
certain point, which was previously shown in other studies [58, 62, 64, 68]. However, the 
opposite was true for patients aged ninety years and above in both disease groups, which was 
also in agreement with reports by Roos, Bickel and Menec et al. [33, 84]. Differences in terms of 
disease expression and therapy response might exist in different age groups, indicating a 
variation in the provision of hospital services in sub-groups. In addition, this inconsistency might 
be related to variations in decision-making among patients in different age groups, particularly in 
those with chronic disorders. For example, for the severely ill older patients, the long-term 
services were more likely to be allocated as compared with the younger generation due to their 
decreased ability to complete daily activities and the presence of multiple comorbid conditions, 
as indicated by a prior study conducted in Amsterdam in 2004 [96].  
 
The most surprising finding in this study was that age had an inverse relationship with the 
number of hospitalizations; although it was hypothesized that advancing age would increase the 
likelihood of hospital service usage. This was an unexpected finding that poses some difficulty in 
its interpretation and therefore merits attention for further research. Patients’ treatment refusal 
was one possible explanation for this inconsistency, especially among the elderly with poor 
health conditions, a hypothesis supported by the work of Berghmans and colleagues in 2002 
[82]. This group found that patients aged seventy years and above were often reluctant to receive 
the standard cancer treatment in Belgium [82]. Some factors in the previous study associated 
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with treatment avoidance included poor patient-physician communication, time constraints, 
physical discomfort, distrust of medical procedures, memories of unpleasant past experiences of 
self or others, as well as negative perceptions of the health care system provided for patients 
living with lung cancer. Two other studies in cancer also found that age was an inverse predictor 
of undergoing treatment [97, 98].  
 
Townsley and colleagues, in 2005, also observed a change in decision-making over the course of 
life in the province of Ontario, Canada [80].  Older adults were more likely to reject a treatment 
plan if they thought the side-effects outweighed the potential increase in lifespan or other 
benefits from the intervention. The younger generation was less impacted by these factors, but 
more influenced by family responsibilities, leading to a lower refusal rate. In order to accurately 
assess the attitudes and perceptions among patients in different age groups, further research 
investigating these factors need to be conducted. 
 
We also speculate that age significantly influences physicians’ decisions on care planning, a 
hypothesis supported by Angus and colleagues in 2004, who reported an decreased likelihood of 
acute care hospitalization among adults aged eighty years and above at the end of life as 
compared to the younger generation of society in the U.S.[99]. This association was also 
reported in earlier reports with subjects living with different types of carcinoma [80, 97, 99, 
100], indicating better understanding and communication with geriatric patients were needed so 
as to achieve optimal care management. 
 
5.1.3 Sex 
According to our descriptive analysis, significant differences existed between sexes, with a 
higher proportion of male decedents observed in both disease groups, which was consistent with 
another U.S. study in 2002 concluding that COPD and lung cancer were male diseases [101]. 
Regarding the sex differences in the provision of hospital care services, however, it was observed 
that female patients stayed longer in hospitals as compared with their male counterparts in the 
last six months of life. This finding was in line with prior reports focusing on sex differences [68, 
75-77]. Factors contributing to the observed variations included levels of anxiety, perception of 
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breathlessness, differences in disease progression and disease management in different sex 
groups [60, 71, 102]. Whether the female subjects experienced more severe symptoms than the 
males, or whether they had different treatments was not possible to investigate in this 
observational study. Additionally, gender role differences could be another interpretation. The 
fact that women usually look after their partners at home could explain much of the sex 
differences. Another possible explanation was suboptimal care management for women. This 
was initially shown in an UK study that examined cardiovascular diseases in 2000 [61]. 
According to Gan and colleagues, women with the same level of disease severity did not receive 
as aggressive care services as the male patients, which increased the likelihood of females being 
hospitalized in the later stages [61]. This type of bias could also exist in patients with COPD 
since it has been traditionally viewed as a male disease; physicians may fail to pay close 
attention to the females as compared with males in earlier stages. 
 
However, there was no significant difference in terms of LOS in hospital in the one month prior 
to death between males and females. This result was reasonable and was reported in other works 
[67, 71]. We suggested that those with severely impaired health had an equal possibility of being 
hospitalized, which could explain much of this finding. As a person approached the end of life, 
the utilization of acute hospital services increased regardless of sex, especially in the last thirty 
days of life; this was also supported by Danish study from Teno and colleagues in 2011[48].  
 
Sex was found to modify the association between disease status and LOS in hospitals, meaning 
that the inverse association with COPD was weaker among males than females. Given the fact 
that tobacco consumption plays a prominent role in the development of COPD [60], significantly 
higher smoking prevalence in males could be one possible explanation [103]. As indicated by 
work from Hunninghake and colleagues, ingredients in cigarettes caused an increase in the 
number of macrophages and neutrophils in the lower airways, leaving greater chance of 
developing lung disorders [104]. Second, female patients were more likely to receive advice 
from physicians. According to a prior UK report from Watson and colleagues in 2004, female 
patients showed better compliance in terms of smoking cessation than their male counterparts, 
suggesting a greater probability of decline in lung function in the male patients [71]. 
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5.1.4 Rural-urban Differences 
Almost half of the decedents were rural dwellers, suggesting that respiratory illnesses were an 
important burden on the health of rural residents. This was especially important given that 
approximately one-third of Saskatchewan residents live in rural areas [105]. An earlier Canadian 
report in 2006 also observed an upward pattern with increasing rurality in terms of mortality 
rates from respiratory diseases for both sexes [106].  
 
According to the results of the multivariate analysis in this study, the difference existing between 
urban and rural residents with respect to LOS in the hospital and number of hospitalizations, was 
consistent with prior reports [59, 107, 108, 109]. Graverholt noted that, in 2014, hospital care 
utilization was not only influenced by patients’ needs, but also dependent upon the availability of 
hospitals and nursing homes in the local area [110]. In 2001, results from the National Family 
Physician Workforce Survey suggested that rural dwellers had poorer access to long-term care 
services but greater access to acute hospital care than their urban counterparts [111].  
 
Observed variations in the hospital care utilization may reflect limitations in access to health care 
for a large number of Saskatchewan residents, particularly those living in rural areas. Complex 
disease conditions often require lengthier hospital stays, especially when services are limited. 
Furthermore, long commutes to hospitals may discourage people from being discharged since re-
admission might be needed as health conditions deteriorate. Improvements in end-of-life care 
services among rural patients should be expanded. For example, the use of telehealth technology 
could maximize the efficiency of treatment, particularly for those residing far from the nearest 
hospital. 
 
Additional factors might also underlie the urban-rural differences. For example, home care 
resource availability would influence the utilization of hospital services, suggesting a greater 
dependence upon home support system by people living in rural regions [112].  
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5.1.5 Comorbid Conditions 
Patients with either COPD or lung cancer experienced a significant number of comorbid 
illnesses, which was consistent with findings in other studies [83, 86]. Many factors contributed 
to the high risk of comorbidity, as cited by Fabbri and colleagues, such as decreased function in 
terms of physiology and immunity [113].    
 
Patients with multiple comorbid conditions typically made high use of hospital services [78]. We 
found that individuals living with more than two comorbid illnesses were more likely to stay 
longer in hospital, which was also reported in prior studies [62, 64, 74, 114]. In 2003, Kinnunen 
and colleagues in Finland demonstrated the great effect of comorbidity on the duration of 
hospital stay, reporting an average LOS of 7.7 days without any comorbid condition compared 
with 10.5 days if any co-existing disease was present [114].  
 
In marked contrast to other studies, however, our findings suggested that multiple comorbid 
conditions was a contributing factor of lower number of hospitalizations, which was inconsistent 
with traditional views [51]. As cited by Anthonisen and colleagues, in 2002, almost half of the 
hospitalizations were due to co-existing chronic conditions in patients living with respiratory 
illness in the U.S. We speculated that the greater use of other types of services, including hospice 
care, family physician visits, and nursing homes, might explain much of the inconsistencies. In 
addition, patients’ reluctance of being hospitalized could be another interpretation [97, 98]. 
Patients living with COPD in the earlier stage were usually admitted to hospitals more frequently 
than those living with lung cancer, leaving the COPD population more averse towards acute care 
settings [98]. 
 
5.1.6 Location of Death 
We found a similar proportion of patients dying in acute care hospitals with studies conducted in 
other provinces in Canada, where rates were reported to be seventy percent or above [46, 55, 
115]. The majority of deaths occurred in hospital settings suggesting that opportunities may exist 
to facilitate desired home deaths at a national level, such as a palliative care tele-health network. 
Earlier research from Nova Scotia in 2012 studied contributing factors of location of death. They 
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observed that urban dwellers were more likely to die out of hospitals [46]. In light of these earlier 
results, our finding that the majority of deaths occurred in the hospitals might be expected since 
nearly half of the study population was residing in rural areas and alternate care may not be 
available. 
 
Patients with end-stage COPD were less likely to die in hospital when compared with patients 
living with lung cancer, which was inconsistent with findings of Edmonds and colleagues in 
2001 [105]. Sudden death could partly explain the observation, which occurred more commonly 
in patients living with multiple comorbid conditions, such as cardiovascular comorbidity, a 
hypothesis supported by the work by McGarvey and colleagues in 2007 [116]. They noted that, 
in a total of 911 deaths, cardiovascular cause accounted for more than one quarter of the study 
population, with the most common cause being sudden death.  
 
However, an earlier study in Nova Scotia in 2003 suggested that long-term supportive service 
was a predictor of out-of-hospital death [46]. In other words, when a person had greater 
consumption in supportive care institution, the likelihood of hospital death decreased.  Our 
findings that the relatively fewer hospital-deaths observed in the COPD population seemed 
logical, because, the proportion of deceased COPD patients receiving supportive care was larger 
than that in the lung cancer group.  
 
5.1.7 Marital Status 
In the last six months of life, those who never married were more likely to have a longer hospital 
stay as compared with the married/ common law subjects. Our findings were consistent with 
other studies concluding that the use of hospital services were higher among never married than 
among married subjects [117, 118]. As suggested by work conducted in the U.S. from Gruneir 
and colleagues in 2007, marital status was an important indicator of social support, which 
reflected the quality of care provided in non-hospital settings [119]. We suggest that the hospital 
service usage might be reduced by home care from a spouse among the married decedents, or be 
increased by poorer physical and spiritual conditions observed among those living alone, which 
was in line with the work by Waite and colleagues in 2002 [117]. This group suggested that 
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patients who lived alone were more susceptible to acute disease exacerbations, as compared to 
those with companions, since they had difficulty finding assistance to manage their diseases, 
such as taking medications, maintaining a healthy diet, and regularly attending pulmonary 
rehabilitation program [117]. 
 
Inconsistency occurred in the association between marital status and the number of hospital 
admissions. One possible interpretation could be the lower level of social support experienced by 
those who lived alone. Individuals living with severe illness usually need people responsible for 
transportation to the hospitals. Lack of social support might decrease the likelihood of seeking 
health care services, leading to a decreased number of admissions. Other factors might also 
contribute to a reduced number of hospitalizations, such as personality, educational level, and 
socio-economic status. Although previous study found that living alone was associated with a 
reduced physician visits, it did not affect the likelihood of hospitalizations [120].  
 
5.1.8 Institutional Supportive Care Services 
When compared to the existing literature on institutional supportive care services, our study’s 
results supported the trend found by others that COPD patients were more likely to receive long-
term institutional care services than their lung cancer counterparts in the six months prior to 
death [47, 58].  
 
According to the results of our multivariate analysis, receiving institutional supportive care 
services increased the possibility of staying longer in the hospital in the six months prior to 
death, but it did not affect the number of hospital visits. One interpretation was that people with 
prolonged hospital stay were more likely to receive institutional supportive care after discharge, 
a hypothesis supported by a Singapore study of Saxena and colleagues in 2005; this group 
reported that patients with discharges to nursing home spent significantly longer time in hospital 
as compared with patients who were discharged directly to home [121]. This was also shown 
previously in other studies with cancer populations [122, 123]. Another potential reason for this 
observation was the increased waiting time experienced among patients to be placed in long-term 
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care institutional settings, indicating an unnecessary cost and decreased hospital bed availability 
[123].    
 
However, there was still inconsistency in the literature where a previous U.S. study conducted in 
2003 reported an opposite relationship [75]. McCarthy and others suggested that higher 
utilization of institutional services decreased the likelihood of being hospitalized and having 
prolonged stay in hospitals [75]. 
 
5.1.9 Transfer between Institutional Supportive Care Facilities 
As part of the current study, transfers between the supportive care institutions for both COPD 
and lung cancer patients were also examined. Among those receiving institutional supportive 
care, 4.7% were recorded as having at least one transfer.   
 
Patients' safety has been identified as a priority within different care settings. Preventable 
adverse events, such as infection, falls and adverse drug events, from transfers were discussed 
previously in many studies [124, 125]. A prior U.S. report in 2005 also illustrated that repeated 
transfers could result in disastrous clinical outcomes [125]. 
 
A previous UK study pointed out that unnecessary transfers were frequently observed in patients 
in different disease categories, resulting in avoidable adverse events that outweigh the benefits of 
transfer, such as closer monitoring and better diagnostic equipment [126]. Consequences of 
unnecessary transfers were especially severe for terminally ill patients, which might lead to 
greater burden on health care utilization, indicating impaired quality of life [126]. 
 
The higher incidence of transfers observed in the COPD population when compared with the 
lung cancer group, had the potential to diminish quality of life in this population. More attention 
is needed from clinicians and policy makers to address this concern. Furthermore, more transfers 
may also reflect the great variability in predicting the disease progression, with episodes of acute 
exacerbations during stable deterioration. Unlike lung cancer patients, it is difficult for health 
care providers to identify the terminal phase of illness for COPD population, leaving a poor 
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patient education and discussion regarding end-of-life care preferences, which in turn increases 
the likelihood of transfers during exacerbations. As cited by Elkington and colleagues, half of the 
subjects dying from COPD did not recognize their trajectory toward death in their last year of 
life [42]. 
 
Our findings suggest an increased risk of longer stay in hospitals in the transferred group within 
the last 6 months of life, which were also demonstrated in previous studies [127, 128]. However, 
the model revealed the hospital utilization (Total LOS, Average LOS and number of 
hospitalizations) to be significantly less in the transferred group of patients in the last one month 
of life, a finding that was somewhat unexpected. Some factors may explain this observation. 
First, an unpleasant past experience might decrease the likelihood of accepting further transfers 
plan [129]. Second, we only considered those transferred between long-term care institutions. If 
those brought directly to hospitals from long-term care settings were also included, the 
relationship might be changed because respiratory diseases were the second most common 
reason for a transfer between supportive care institutions and hospitals. Based on a study by 
Przybysz and colleagues, in 2009, one in five transferred patients were admitted to acute hospital 
care settings primarily associated with impaired respiratory function in Canada [128]. A 
limitation of the present study was a lack of information on the transfers between hospitals and 
supportive care institutions.  
 
5.1.10 Calendar Year 
Over the 10-year study period, there was no significant change in the utilization of hospital care 
services after adjustment for age, sex, disease status, residence, comorbid conditions, location of 
death, marital status, institutional supportive care services and transfers between supportive care 
institutions. This observation was inconsistent with other studies where a reduction in hospital 
bed use among respiratory patients was noted [75, 91]. A number of factors contributed to the 
disparities in results.   
 
First, significant changes occurred in the Saskatchewan health care system in 1990’s, resulting in 
a reduction in the number of hospital beds [130], which might have created an observed 
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downward trend in hospital bed utilization in prior reports. This was also associated with time 
spent in hospital and was described in other Canadian reports [75, 131]. Most studies 
investigated the trends of hospitalization during the last year of life among terminally ill patients; 
however, we were focusing on the patterns during the last six months and one month of life. 
Given the fact that people’s health condition deteriorates dramatically in the weeks prior to 
death, their possibility of being hospitalized may not change as much as those in their last year of 
life. 
 
Second, the way we managed the data could, in part, explain the disparities. We combined two 
admissions into one event if a patient was readmitted to a hospital on the same day of 
discharging from another hospital, resulting in a slightly smaller number of hospital visits when 
compared with those who counted two admissions as two events. As a result, the total LOS in 
hospitals remained same, but the denominator became smaller, it was more likely to get a larger 
average LOS per visit.  
 
Additional factors may have also influenced the patterns of hospital services utilization, such as 
the use of palliative care services, physician’s decision on care planning, and patient’s preference 
on the location of care, which was not possible to be assessed in the current study due to the 
limited information from administrative data.  
 
5.2 Strengths and limitations 
5.2.1 Strengths 
Administrative data provides an efficient and economical tool in measuring the care utilization at 
the end of life among individuals who died from lung cancer and COPD. Since the data were 
continuously collected, and were population-based over the study period without intent for a 
specific research project, the risk of bias was decreased. An almost universal population within 
Saskatchewan was used. The use of Saskatchewan Health data also allows us to measure the 
trends for hospital utilization at the end of life through data linkage of existing files.    
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In addition, our method enabled us to report the LOS in hospitals as well as the number of 
admissions near the end of life among decedents with COPD and lung cancer, which was more 
informative than those only focusing on whether the patient died in hospital or not.  
 
A group of decedents from lung cancer was used as a comparison group in this study. This has 
the advantage of using a comparison group that could control some external confounders that 
may account for the changes in hospitalizations. Additionally, without a comparison group (i.e. 
lung cancer patients), we would not be able to fully explain the seriousness of health conditions 
among the advanced COPD patients. Thus, this study could examine whether these patients 
living with COPD are relatively disadvantaged in terms of medical care when being compared 
with a group with terminal lung cancer. 
 
A previous report illustrated the significant impact from double counting from inter-hospital 
transfers, and suggested that it should be considered or corrected when conducting and 
interpreting research [132]. In order to avoid transfer bias, we counted a patient who was 
readmitted to another hospital on the same day of discharging from an existing hospital as having 
one transfer, and combine two hospitalizations rather than counting it as a second admission. 
Various time frames for identifying a transfer were applied in previous studies [132, 133]; our 
decision was made to minimize the possibility of double counting.  
 
5.2.2 Limitations  
Our findings are subject to several limitations. The main purpose of this study was to measure 
the quality of care provided for patients near death, which is, ideally, measured by whether the 
right care is given to the right patient in the right way in the right amount and at the right time. 
However, we had no information on patients’ preferences for end-of-life services or on patients’ 
satisfaction with the care provided during hospitalization, for example, the effectiveness of pain 
control, or the emotional or physical support provided by the nursing staff.  
 
Second, the administrative data provides information regarding the frequency of hospital 
attendance and duration for each hospitalization; however, it doesn’t contain information on the 
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improvement in patients’ health, which has great clinical and political implication. Previous 
literature showed that terminal cancer patients were routinely given surgery or other treatments 
even though the treatments would bring them no benefit [91]. If the treatment intensity doesn’t 
correspond to the improvement of patients’ health or satisfaction, we would question the 
efficiency of the health care system. Thus, suboptimal care management among critically ill 
patients makes a strong case for more intensive research and analysis. Unfortunately, we cannot 
relate services provided in hospitals to health outcomes, thus, we are not able to reach 
conclusions regarding the efficiency of the current care system. Moreover, quality of life for both 
disease groups in terms of emotional wellbeing is not possible to be investigated in the current 
study, although it is considered as an important component in health evaluation [134].  
 
Furthermore, this study investigated only in-patient hospitalizations. We did not consider 
hospitalizations that were managed in outpatient settings or in emergency departments, due to the 
lack of information on these topics available, suggesting a substantial underestimation of the 
hospital service consumption. In addition, information on time spent in ICU is missing. Some 
research suggested a significant relationship between transfer and ICU consumption. According 
to Golestanian and colleagues, in contrast to the non-transfer clients, the transferred group 
consumed greater resources in both regular in-patient and intensive care settings because of their 
severely impaired health condition [127]. Unfortunately, the data does not contain information 
on LOS in ICU, leaving much difficulty in measuring the effect from transfer. In addition, sex 
may also influence the number of days spent in ICU, which provides us an opportunity to 
examine the quality of end-of-life care for the study population between sexes. Thus, we were 
not able to examine this in administrative data. 
 
First Nations people were excluded in the analysis due to the way residence is coded in the 
administrative database. However, First Nations people constitute about 9% of the Saskatchewan 
population. In addition, a higher percentage of COPD in both morbidity and mortality have been 
observed in this population in previous studies [13, 14]. This limitation could lead to an 
underestimation of the hospital service utilization and lack of generalizability to this group. 
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The results of this study represent only one Canadian province. It may be difficult to generalize 
the findings nationally due to the regional scope of the study. Additionally, we only observed 
patients who died from COPD or lung cancer, which may limit the relevance of the findings to 
patients who died from other respiratory diseases. 
 
Although the number of cases of COPD has increased in the last 20 years, COPD has been 
infrequently mentioned as a contributing or underlying cause of death even in patients with 
severe diseases [15, 32], but more likely as a contributory cause of death [60, 136]. Some authors 
argued that this would result in underestimation of a true association. An earlier European study 
reported a substantial underestimate on the number of deaths to which obstructive lung disease 
makes a contribution. Where obstructive lung disease was mentioned but not the underlying 
cause of death, the other most common causes were heart disease and lung cancer. In North 
America, work in the USA [32] also suggested that using underlying cause of death as an 
indicator of the health burden from severe COPD might dramatically underestimate the impact of 
the disease, with non-respiratory causes accounting for 50% of the underlying causes of death in 
COPD patients in the USA. Thus, COPD is likely to be underreported on death certificates in our 
cohort study. 
 
Given the nature of the retrospective study design and that we used administrative databases, it is 
certainly possible that some other confounding variables were missed or poorly documented. For 
instance, smoking history, material deprivation level, and home support is not available from 
administrative data. This could potentially lead to a biased estimate due to confounding. 
 
Age is the independent variable of primary interest in this study. The descriptive analysis 
suggests that people who died of COPD are on average older than those who died of lung cancer. 
This might result in a biased result because the older adults are more likely to be managed in the 
long-term care facilities than the acute hospital settings, leaving patients with COPD a reduced 
risk of being hospitalized. None of the predefined indicators in the study, however, is a direct 
measure of the quality of end-of-life care. For instance, one person can die at home suffering 
great distress without any care, and another, can die in an intensive unit with good pain control 
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and ample emotional support from the nursing staff. However, all variables included in this study 
were based on the recent literature. 
 
5.4 Causal Inference in Epidemiology 
Causality was also considered in this study as suggested by Hill's criteria [135]. First, although 
this was a case-control study in nature, temporality was established due to the way data was 
recorded in the administrative file. Second, the findings demonstrated strong and statistically 
significant associations between the main effect factors (age, sex, comorbidity and disease status) 
and hospital service utilization. Third, since the findings were consistent with some earlier 
research in given literature, consistency was achieved. Finally, some of the current findings were 
not plausible based on literature. For example, we found that age and comorbidity were negative 
predictors of frequent hospital admissions, which was also inconsistent with our hypothesis. 
Although there was some concern of misclassification bias suggested by current literature, this 
type of bias occurs were at random and would have had little effect on the true relationship 
between disease status and hospital service utilization. 
 
5.3 Implications 
Issues pertaining to advanced COPD affect millions of individuals around the world. Our study 
attempted to identify trends in hospital care utilization among terminally ill COPD patients with 
specific emphasis on how sex, age and comorbidity affected the trends. We expect the findings 
would provide the basis for establishing recommendations on how to improve the quality of end-
of-life care among individual living with advanced COPD. Furthermore, we hope the findings 
would make a tangible contribution to the development of palliative care that allow for unique 
needs based on sex. 
 
5.4 Recommendations 
ICU has been acknowledged as an important component of acute hospital care services. Initially, 
we were interested in looking at the relationship between main effect factors and LOS in 
intensive care settings. However, due to the large amount of missing information for this 
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variable, it could not be examined. Therefore, a study investigating the association between 
disease status and LOS in ICU is required in the future. 
 
We also suggest that more information regarding the patient's attitudes towards advance care 
planning should be collected for further research as the primary objective is to investigate 
whether the optimal quality of life is achieved after receiving end-of-life services among those 
who are expected to live less than six months. 
 
There were no significant trends observed in the current study regarding the hospital services 
utilization over a 10-year study period, which was inconsistent with prior reports. We would 
suggest collecting more information on services provided in other care settings, such as 
emergency room, out-patient settings and clinics, etc. This would allow an in-depth examination 
regarding what types of institutional services influenced the usage of in-patient care.  
 
Advancing age and multiple comorbid conditions showed inverse associations with frequent 
hospital attendance. Even though these factors were consistent with some studies in given 
literature, more investigation was required to explore the reasons behind it. Confounding factors 
such as smoking history, communication between physician and patients, patients' preference on 
care planning and patient's disease severity, may affect the true relationship. Thus, they should 
be considered in the multivariate analysis in future studies for more persuading result.  
 
Only one province of Canada was investigated in the current study, thus it was not possible to 
generalize the findings nationally. We would suggest further research at a national level. 
 
5.5 Conclusions 
Marked differences in terms of hospital service utilization in the last six months of life were 
observed between subjects dying with COPD and lung cancer. Our findings also suggested that 
the care utilization at the end of life could be attributed to factors in the health care utilization 
framework developed by Andersen, Aday and others [75]. Predisposing factors, such as younger 
age, significantly contributed to frequent hospital admissions, while older people were more 
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likely to stay longer in each admission. A higher rurality predicted an increased likelihood of 
greater hospital service utilization, indicating that enabling factors, such as the rural-urban nature 
of the community in which the subjects live, played an important role in predicting the 
probability of hospital services use among those in their last phase of life. In addition, need 
variables, such as comorbid conditions, were also related with the care delivery. For example, a 
prolonged LOS in hospitals was clearly associated with a higher number of comorbid conditions. 
 
In summary, the complex nature of chronic respiratory diseases presents a challenge for all care 
providers. Overall, patients dying from COPD were on average older than those who died from 
lung cancer. Furthermore, compared with those who died from lung cancer, people dying from 
COPD were less likely to be admitted to hospitals and had shorter LOS for each admission 
although their physical and psychosocial symptoms were as severe as their lung cancer 
counterparts; however, they were more frequently managed in the intensive care settings and had 
higher numbers of transfers between long-term care facilities. Education of all health care 
professionals on the complex needs of patients living with respiratory illnesses is required. 
Considering the variability of COPD progression, palliative care services should be available at 
the earlier stage instead of at the end stage. In addition, individual determinants of health service 
utilization, including the predisposing personal characteristics, the enabling factors, and factors 
that reflected the need of care, play an important role in predicting the hospital services usage 
among those towards the end of life. Policy makers should keep these factors in mind when 
establishing regulations in health service delivery. 
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